

REVIEW

Open Access



# Intratumor heterogeneity: the hidden barrier to immunotherapy against MSI tumors from the perspective of IFN- $\gamma$ signaling and tumor-infiltrating lymphocytes

Wantao Wu<sup>1,2†</sup>, Yihan Liu<sup>1,2†</sup>, Shan Zeng<sup>1,2,3\*</sup>, Ying Han<sup>1,2,3\*</sup> and Hong Shen<sup>1,2,3\*</sup> 

## Abstract

In this era of precision medicine, with the help of biomarkers, immunotherapy has significantly improved prognosis of many patients with malignant tumor. Deficient mismatch repair (dMMR)/microsatellite instability (MSI) status is used as a biomarker in clinical practice to predict favorable response to immunotherapy and prognosis. MSI is an important characteristic which facilitates mutation and improves the likelihood of a favorable response to immunotherapy. However, many patients with dMMR/MSI still respond poorly to immunotherapies, which partly results from intratumor heterogeneity propelled by dMMR/MSI. In this review, we discuss how dMMR/MSI facilitates mutations in tumor cells and generates intratumor heterogeneity, especially through type II interferon (IFN- $\gamma$ ) signaling and tumor-infiltrating lymphocytes (TILs). We discuss the mechanism of immunotherapy from the perspective of dMMR/MSI, molecular pathways and TILs, and we discuss how intratumor heterogeneity hinders the therapeutic effect of immunotherapy. Finally, we summarize present techniques and strategies to look at the tumor as a whole to design personalized regimes and achieve favorable prognosis.

**Keywords:** Microsatellite instability, Immunotherapy, Tumor-infiltrating lymphocytes, IFN- $\gamma$  signaling, Heterogeneity

## Background

Immunotherapies have had promising effects on many cancer patients. In order to evaluate the response to immunotherapy, deficient mismatch repair (dMMR)/microsatellite instability (MSI) status has been widely exploited by practitioners, since it is found extensively across diverse types of cancer. dMMR/MSI is associated with improved outcomes independently of other clinical prognostic factors, such as disease stage [1]. Therefore, many clinical researchers suggest that dMMR/MSI

contributes to high efficacy of immunotherapy in different tumor types [2–4].

Deficient MMR system and instable genomic status led to accumulation of somatic mutations, especially frameshift mutations [2], which generate subclones with neoantigens. These neoantigens are recognized as non-self and elicit anti-tumor responses including higher tumor-infiltrating lymphocyte (TIL) grade and expression of type II interferon (IFN- $\gamma$ )-related genes, such as those encoding programmed cell death 1 ligand 1 (PD-L1), cytotoxic T lymphocyte-associated antigen-4 (CTLA-4), lymphocyte activation gene-3 (LAG-3) and indolamine-2,3-dioxygenase (IDO) [5, 6]. Nevertheless, as the depth of research grows, dMMR/MSI has been regarded as a double-edged sword in immunotherapy. That is, dMMR/MSI also correlates with resistance to

\*Correspondence: zengshan2000@csu.edu.cn; yinghan@csu.edu.cn; hongshen2000@csu.edu.cn

†Wantao Wu and Yihan Liu have contributed equally to this work

<sup>1</sup> Department of Oncology, Xiangya Hospital, Central South University, Changsha, Hunan, People's Republic of China 410008


Full list of author information is available at the end of the article



immunotherapy, resulting from complex mechanisms such as frequent immunoeediting of WNT/ $\beta$ -catenin signaling, antigen presentation machinery and IFN- $\gamma$  signaling [7–11].

dMMR/MSI is one of the most important drivers of intratumor heterogeneity (ITH) [12], which refers to the different states within a tumor such as genomic instability, epigenetic abnormality, acetylation, gene expression dysregulation, post-translation modifications, biological behaviors, tumor microenvironment, T cell receptor and heterogeneous response to therapies [13]. ITH is present spatially and temporally. Spatial heterogeneity is defined as distinct genetic alterations and phenotypes between tumor cells; while temporal heterogeneity is embodied in the evolvement of subclones during natural tumor progressing and therapeutic interventions. Generally, tumors start out as a heterogeneous mixture, and immune selective pressure imposed by immunotherapy facilitates outgrowth of resistant clones and elimination of sensitive ones. ITH is found in a variety of tumors and predicts prognosis of targeted therapies [14].

ITH may result in sampling bias of biomarkers in cancer immunotherapy, such as programmed cell death protein-1 (PD-1), tumor mutation burden (TMB) and dMMR/MSI, and lead to entirely different clinical consequences. In other words, the current single tumor specimen underestimates the genomic spectrum variety across the tumor [15]. Different technologies have been invented to enable simultaneous deep analysis of single cells integrating genome, epigenome and transcriptome information [16]. ITH characterization is better than ever through bulk cell profile analysis and depiction of single cells in different regions via multiomics and is shown to significantly impact the immune response and prognosis of cancer patients (Fig. 1). Studies show that increased ITH is associated with worse anti-PD-1 therapy efficacy and “biomarker-oriented heterogeneity” determines drug sensitivity of each subclone [17–19]. These phenomena may explain why prognosis for a large proportion of patients remains poor after immunotherapy treatment with the target molecule. Therefore, ITH is a huge obstacle in treating tumors effectively.



**Fig. 1** Progression of MSI tumor. In dMMR tumors, dysfunction in mismatch repair system cannot repair DNA mismatches, leading to DNA sequence alterations especially in microsatellites. With the accumulation of DNA sequence alterations, the tumor mutation burden gradually grows, and tumor cells are evolving into different subclones harboring heterogeneous neoantigens and characteristics. The application of immunotherapy eliminates many tumor cells and puts tumor under immune selection and immunoeediting. Subclones which are resistant to immunotherapy grow out. Finally, the treatment-resistant primary tumor and metastases with heterogeneous subclones progress. Besides, status of MMR within a tumor is heterogeneous. MSS tumor cells may exist in dMMR/MSI tumors as well, and these cells do not respond to immunotherapy at the first place. As many of the MSI cells are eliminated, MSS tumor cells can grow out, leading to resistance to immunotherapy. Therefore, utilizing new detection methods to combat ITH is crucial to characterize tumor landscape

In this review, we discuss the two-sided effects of dMMR/MSI on immunotherapy. We summarize recent immunotherapy studies, including immune checkpoint blockade (ICB), adoptive cell transfer (ACT) and vaccine, and explore the effect of ITH on factors such as dMMR/MSI, TIL, IFN- $\gamma$  and immune checkpoints. Due to the widespread effects of ITH in tumors [20], methods to combat spatial and temporal heterogeneity should be utilized to learn the big picture of tumor and guide therapy selection. We review the latest advances in single-cell sequencing and liquid biopsy, including circulating tumor DNA (ctDNA) and circulating tumor cells (CTC). Dynamic tumor cell profiling could translate into clinical applications for promising tumor therapy in the near future.


### MSI plays a vital role in the generation of intratumor heterogeneity

dMMR/MSI is generalized across different cancer types, occurring with different frequencies and signatures. It is most commonly found in colorectal, endometrial and gastric cancers, but also in ovarian, cervical and prostate cancers [21–25] (Table 1). The MMR system consists of four major proteins: MLH1, MSH2, MSH6 and PMS2, which identify and correct DNA mismatches in the form of heterodimers: MLH1 couples with PMS2, PMS1 or MLH3 (forming MutL $\alpha$ , MutL $\beta$  or MutL $\gamma$  complexes), and MSH2 couples with MSH6 or MSH3 (forming MutS $\alpha$  and MutS $\beta$  complexes) [26, 27]. MutS $\alpha$  could recognize DNA mismatched base errors, create a sliding clamp around DNA, undergo an ATP-driven conformational switch and subsequently bind MutL $\alpha$  to interact with enzymes such as DNA polymerase, excise the mismatch and resynthesize DNA [27–29] (Fig. 2). Germline mutations in MMR genes, epigenetic hypermethylation of MMR gene promoter or biallelic somatic inactivation of MMR genes could lead to loss of MMR protein expression [30]. Among them, loss of MLH1 and/or PMS2 occurs at higher frequency than loss of MSH2 or MSH6, and loss of MLH1/PMS2 co-expression is more common than loss of MSH2/MSH6 co-expression [31] (Table 2). Tumors with at least one MMR protein loss by immunohistochemical (IHC) detection are called dMMR tumors, in contrast to MMR-proficient (pMMR) tumors. And generally, loss of MLH1 or MSH2 leads to degradation of PMS2 or MSH6, respectively [29]. A deficient MMR system is likely to cause DNA sequence alterations especially in microsatellites, which are short tandem repeats scattered throughout the genome. An accumulation of errors in the microsatellites is called MSI, a hypermutator phenotype associated with hereditary and sporadic tumors [27]. Based on microsatellite loci analysis, tumors with an instability of at least two loci out of BAT-25, BAT-26,

**Table 1** Frequency of dMMR/MSI across tumors

Tumor type	dMMR/MSI (%)	References
CRC	19	[21]
	17	[243, 244]
	15	[25]
	8	[245]
	6	[2]
EC	33	[246]
	30	[21]
	28	[244]
GC	17	[2]
	22	[247]
	21	[244]
OC	15	[25]
	8	[2]
	12	[25]
Cervical cancer	10	[248]
	2–3	[2, 21, 244]
Prostate cancer	2–10	[24]
	2–3	[2, 244]
HCC	<2%	[24]
	1–2	[2, 21, 244]
PC	16	[249]
	2–3	[2, 244]
GBM	1–2	[2, 244]
	1	[2, 244]
HNSCC	1	[21, 244]
	2	[250]
RCC	1–2	[21, 244]
	28.1	[251]
Lung adenocarcinoma	<1	[2, 21]
	0	[244]
Lung squamous cell cancer	1	[21, 244]
	2	[2]
Cholangiocarcinoma	2	[2]
	9	[244]
Rectal cancer	3	[21]
	10	[252]
Ampullary carcinoma	2	[2]
	17–31.37	[29]
Thyroid cancer	4.35	[29]
	1.63	[29]
UCEC	1	[202]
	0–0.64	[29]
ACC		
ESCA		
SKCM		

CRC Colorectal cancer, EC Endometrial cancer, GC Gastric cancer, OC Ovarian cancer, HCC Hepatocellular cancer, PC Pancreatic carcinoma, GBM Glioblastoma multiforme, HNSCC Head and neck squamous cell carcinoma, RCC Renal cell cancer, UTUC Upper tract urothelial carcinoma, UCEC uterine corpus endometrial carcinoma, ACC adrenocortical carcinoma, ESCA esophageal carcinoma, SKCM skin cutaneous melanoma



D2S123, D5S346, D17S250 (Bethesda panel) or three loci out of BAT-25, BAT-26, NR-21, NR-24, NR-27 (Pentaplex panel) are considered as MSI, in contrast to microsatellite stable (MSS) [2, 28].

BRAF V600E mutation is often associated with MLH1 promoter hypermethylation, resulting in simultaneous loss of MLH1 and PMS2, which has been reported in 70% of dMMR/MSI tumors [24, 32]. BRAF mutation is related to negative prognosis in CRC, but due to its strong association with MSI phenotype, studies found that the positive prognosis impact of MSI could alleviate or overcome the negative effect [33, 34]. Furthermore, immunotherapy combined with BRAF inhibitor has been found to benefit patients with BRAF mutation, providing additional treatment target for patients

unlikely to have long-lasting response to immunotherapy alone [35]. Moreover, the latest studies found that TA-dinucleotide repeats were highly unstable in dMMR/MSI cells and underwent large-scale expansions. Werner helicase (WRN), a member of the RecQ family of DNA helicases crucial for maintaining genome stability, was important to avoid TA-dinucleotide repeats cleavage and massive chromosome shattering [36], indicating WRN as a synthetic lethal vulnerability for dMMR/MSI tumors. Indeed, the dependency of WRN was observed widespread in dMMR/MSI tumors [37]. WRN knockout could induce double-strand DNA breaks, and selectively impair the viability of dMMR/MSI cells by nuclear abnormalities and cell division defects, which might be influenced by the loss of MSH2 or MLH1 [38, 39] (Fig. 2). Due

**Table 2** Frequency of loss of MMR proteins across tumors

MLH1 (%)	PMS2 (%)	MSH2 (%)	MSH6 (%)	MutLa(MLH1/PMS2)(%)	MutSa(MSH2/MSH6) (%)	Tumor type	N	Reference
78.2	82	12.1	15.9	77.2	11.5	MSI solid tumors	1057	[31]
N/A	N/A	N/A	N/A	3.7	1.8	GC	107	[253]
N/A	1.8	N/A	N/A	20.4	5.3	CRC	113	[254]
N/A	N/A	5.9	11.8	41.2	N/A	Undifferentiated GIC and PC	17	[255]
30.2	34.9	55.8	46.5	N/A	N/A	High-grade gliomas	355	[256]
7.1(partially negative)	7.1(partially negative)	7.1(partially negative)	7.1(partially negative)	N/A	N/A	Primary GBM	57	[257]
7.1(partially negative)	7.1(partially negative),7.1(completely negative)	14.3(partially negative),7.1(completely negative)	57.1(partially negative),28.6(completely negative)	N/A	N/A	Recurrent GBM	57	[257]
0.9	12.3	2.7	16.8	N/A	N/A	Prostate cancer	220	[258]
59.5	67.6	18.9	32.4	N/A	N/A	Endometrial endometrioid adenocarcinoma	107	[259]
23.8	N/A	14.8	9.3	N/A	N/A	Endometrioid endometrial carcinoma	486	[260]
83.34	3.33	1.37	4.11	N/A	N/A	CRC	1000	[261]
20	13.3	33.3	33.3	N/A	N/A	CRC,EC	15	[262]
23	N/A	N/A	N/A	N/A	N/A	pNETs	48	[263]
36	N/A	16	N/A	N/A	N/A	pNETs	55	[264]

GC Gastric cancer, CRC Colorectal cancer, GIC Gastrointestinal cancer, PC Pancreatic carcinoma, GBM Glioblastoma multiforme, EC Endometrial cancer, Pnet Pancreatic neuroendocrine tumor, N/A Not applicable

to the finding that WRN dependency was associated with resistance to immunotherapy in dMMR/MSI CRC models [40], WRN may serve as a potential target for treating dMMR/MSI tumors.

Essentially, dMMR/MSI facilitates the process of mutations in tumor cells and propels ITH, leading to the immune evasion of tumors [41, 42]. A systemic review by European Society for Medical Oncology described high percentages of concurrence of TMB-high and MSI-high in cancers such as colorectal cancers and endometrial cancers [43]. In an analysis of glioma, defects in mismatch repair (MMR) genes were found to play a vital role in the pathways to high tumor mutational burden [44]. Even though TMB has been used as a predictor for immunotherapy response, researches have noticed that tumors with equally high TMB levels presented with diverse immune response [45]. A key cause is that TMB resulted from increased genomic instability is

considered the fundamental contributor of ITH [12]. In a mouse model, researchers managed to uncouple effects of ITH and TMB, and they discovered that ITH can be a predictor of immunotherapy response independent of TMB [46]. During tissue repair, inflammation and injury-induced cell turnover may inevitably lead to mutation acquisition; subsequently, mutations generated through this process are faced with natural selection pressure by the host's immune response (Fig. 1). With the joint effort of intratumoral competition and immunoeediting, this evolutionary process may result in ITH with a unique mutational composition across the lesion [47]. One study found that most mutational signatures are ubiquitous between normal colon cancer recesses and adjacent normal recesses and sporadic mutations are not significantly different either. Nevertheless, mutations in specific genes (BRAF, APC, KRAS, TP53, etc.) are more frequent in those with colon cancer [48].

Immunotherapy not only acts as a strong immune selection pressure through which subclones bearing pre-existing resistant phenotype grow out, but also generates new subclone driver events [41, 49]. This change in mutation landscape after treatment contributes to temporal intratumor heterogeneity, and temporal response and follow-up are especially important in response to treatment; while change of the subclones is bound to change in the immune response. In colorectal cancer associated with colitis, cancer cells undergo genetic mutations in the early stage of tumorigenesis [50]. In some cancer types, the driver mutations and DNA methylation level may be determined in the early stage of tumorigenesis [51, 52]. In polyclonal tumors, significant tumor heterogeneity is discovered by seeding the initiating sublineages at the early stage [42]. In some other tumors, tumor evolution in branched sublineages makes up most driver mutations of tumorigenesis [53]. No matter what evolution process the tumor takes, they present ITH. In studies covering several cancer types, ITH has been deemed as a symbol of tumor progression, as high ITH often correlates with decreased immune activity and exhausted immune microenvironment [44, 54, 55]. ITH in the expression level of IFN- $\gamma$  and TILs influences the efficacy of immunotherapy. Among diverse groups of TILs, our review focuses on tumor-infiltrating T cells that are directly linked to cytotoxic effects against tumor cells and their ITH is well studied.

IFN- $\gamma$  is a major member of the IFN cytokine superfamily produced by T cells and nature killer (NK) cells upon the recognition of tumor antigens. It has a wide range of biological functions such as antiviral, anti-tumor and immune regulation, through induction of multiple proteins via IFN- $\gamma$  stimulated genes (ISGs). With the discovery that the expression of PD-L1 within tumors is focal and heterogeneous both spatially and temporally [47, 56, 57], other studies on ITH of IFN- $\gamma$  signaling have been published in succession. In the lung adenocarcinoma (LUAD) patient-derived xenografts (PDXs), Ke-Yue Ma et al. discovered that IFN- $\gamma$  signaling pathway genes were heterogeneous and coregulated with other immune-related genes including PD-L1, MHCII and IDO. The downregulation of IFN- $\gamma$  signaling is associated with an acquired phenotypic resistance [58].

Somatic mutations of tumor are essential for neoantigen expression and consequent immune infiltration [2, 59]. Antigen-presenting cells and TILs play an indispensable role in recognizing tumor neoantigens and generating cytotoxic effects against tumor cells. The process of neoantigen presentation and mechanisms by which tumor cells evade immune recognition have been reviewed elsewhere [60]. Among TILs, ITH of the T cell repertoire has been widely recognized, and T cell

clusters bring about pivotal and direct effects on tumors, which is the focus of this review. The two-sided role of B cells and the antibody repertoire has been delineated elsewhere [61]. For patients who respond to immunotherapy, the vanished tumor neoantigen is in line with the expansion of TIL clonotypes [62]. Theoretically, the greater the mutation burden of a tumor, the stronger the provoked immune response. TMB, a biomarker reflecting the mutation degree of tumor cells, is positively linked with the prognosis of patients receiving immune checkpoint inhibitors in many cancer types [63, 64]. However, growing heterogeneity in intratumoral neoantigens leads to increasing heterogeneity in TILs against tumor cells and in the immune microenvironment [65–67]. A study found liver cancer evolved from different liver diseases may have a distinctive T cell receptor (TCR) repertoire [68]. Consequently, the T cell repertoire coevolves with the tumor cell mutations, and gradually manifests a landscape distinct from those in adjacent normal tissue [69, 70].

The specificity of infiltrating T cells against tumor cells originates from the T cell receptor. Through TCR sequencing, intratumoral T cell heterogeneity with respect to infiltration status, clonality and TCR repertoire was fully characterized in various tumor types. Both spatial and temporal heterogeneity of the immune composition and TCR repertoire in the tumor microenvironment may be pivotal to the fundamentally different responsiveness and prognosis under immunotherapies, as seen in Table 3. The immune responses of different clusters of infiltrating T cells against a tumor are heterogeneous. In one study, clonality and accumulation of high-frequency clonotypes were higher in CD8+ TILs than those of CD4+ TILs, while a higher amount of TCR repertoire diversity was discovered in CD4+ TILs [71]. The complex architecture inside tumors may further complicate the intratumor TCR heterogeneity [72]. Dynamic evaluation of the temporal heterogeneity of TCR repertoire has also been used to reflect immune status, predict distant metastasis after treatment and indicate prognosis [73–75]. The varied vascular and lymphatic spatial distribution may lead to different accessibility to oxygen and nutrients across different regions that shape the microenvironments holding T cells resulting in differing quantities, functions and reactions to neoantigens [72, 76].

The expression of different immunologic elements has long been associated with the prognosis of cancer patients [77–79]. With high TMB and ensuing immune cell infiltration, MSI tumors fall into the type 1 microenvironment according to the category proposed by O'Donnell et al. [80]. As for these tumors, ITH of IFN- $\gamma$  and TIL may be a pivotal factor leading to resistance against immunotherapy.

**Table 3** Representative studies revealing ITH of tumor-infiltrating lymphocytes

Tumor type	References	Heterogeneity type	Main indicators of heterogeneity	Compared region	Relationship with prognosis
NSCLC	[66]	Spatial heterogeneity	Tumor-infiltrating T cells	Ubiquitous and multi-regional tumors	Numbers of expanded ubiquitous or regional intratumoral TCRs are not associated with outcome
LC	[41]	Spatial heterogeneity	CD8 + T cell infiltration	Multi-regional tumors	High clonal neoantigen load and low immune evasion capacity are associated with improved disease-free survival times
Localized LUAD	[72]	Spatial heterogeneity	CD4 + and CD8 + T cells	Centers and margins of tumors	Amount and TCR repertoire ITH of CD4 + and CD8 + TILs in tumor centers and margins are associated with prognosis
Localized LUAD	[65]	Spatial heterogeneity	T cell density and clonality	Multi-regional tumors	ITH in the T cell repertoire is associated with a risk of relapse
Early LUAD	[265]	Spatial heterogeneity	Immune cell atlas	Tumor, adjacent tissue and blood	N/A
ESCC	[266]	Spatial heterogeneity	TCR landscape and PD-L1 expression	Multi-regional tumors, normal tissues and blood samples	High proportion of branch neoantigens is associated with short overall survival
ESCC	[119]	Spatial heterogeneity	T cell clonality	Multi-regional tumors, matched adjacent normal tissue and peripheral blood	N/A
CRC	[267]	Spatial heterogeneity	T cell clones and counts	Tumor and adjacent tissue	N/A
GBM	[84]	Spatial heterogeneity	TIL diversity	Multi-regional tumors	Overall level of the immune response is connected with prognosis
OC	[268]	Spatial heterogeneity	T cell clonality	Multi-regional tumors	Combination of mutational processes and immune properties is associated with prognosis
NPC	[168]	Spatial heterogeneity	T cell clonality	Matched tumor, adjacent normal tissue and peripheral blood	A lower diversity of TCR repertoire in tumors than paired tissues or a low similarity between the paired tissues is associated with a poor prognosis
MEL and CRC	[269]	Spatial heterogeneity	T cell clonality	Multi-regional tumors	N/A
MEL	[166]	Spatial heterogeneity	T cell clonality	Metastases	Homogeneous lesions are associated with response to therapy;
MEL	[270]	Spatial heterogeneity	Single-cell analyses of T cells	Metastases	N/A
HCC	[53]	Spatial heterogeneity	CD8 + T cells infiltration and immune markers	Multifocal tumors	N/A
PC	[105]	Spatial heterogeneity	T cell clonality	Multi-regional tumors and peripheral blood	N/A
RCC	[271]	Spatial heterogeneity	The clonal composition of T cell populations	Multi-regional tumors	N/A
OC	[272]	Spatial heterogeneity	T cell oligoclonal expansion	Metastases	N/A
OC	[273]	Spatial heterogeneity	T cell clonality	Tumor and peripheral blood	N/A

**Table 3** (continued)

Tumor type	References	Heterogeneity type	Main indicators of heterogeneity	Compared region	Relationship with prognosis
BC	[274]	Spatial heterogeneity	T cell clonality	Tumors and lymph nodes	N/A
NSCLC	[127]	Heterogeneity among different levels of PD-1 expression	Transcriptional and metabolic profile of T cells	Different subsets of CD8 <sup>+</sup> TILs	Presence of PD-1 T cells is associated with both response and survival in patients treated with PD-1 blockade
Metastatic MEL	[275]	Heterogeneity among different levels of PD-1 expression	T cell clonality	Metastases	N/A
Metastatic MEL	[126]	Heterogeneity among different levels of PD-1 expression	Phenotypic traits of CD8 <sup>+</sup> TILs and TCR clonotype	Metastases	N/A
CC	[125]	Temporal heterogeneity	Circulating TCR repertoire	Peripheral blood samples throughout carcinogenesis	Less clonotypes in TCR repertoire of sentinel lymphatic node is associated with poor prognosis
GC	[67]	Temporal heterogeneity	TCR repertoire	Tissue samples at different pathological stages	An 11-gene module related to TCR repertoire is correlated with the overall survival of GC patients
LC	[73]	Temporal heterogeneity	Circulating TCR repertoire	Pre- and post-treatment peripheral blood samples	Increased diversity and high overlap rate between the pre- and post-treatment TCR repertoires indicated clinical benefit
NPC	[74]	Temporal heterogeneity	Circulating TCR repertoire	pairwise pre-treatment and post-treatment peripheral blood samples	Ascending TCR diversity and higher similarity between pre- and post-treatment samples showed better distant metastasis-free survival
RCC	[75]	Temporal heterogeneity	Circulating TCR repertoire	peripheral leukocyte samples before and after surgery	Higher baseline TCRB diversity is associated with better prognosis of in stage IV patients
NSCLC	[276]	Temporal heterogeneity	Circulating TCR repertoire	blood samples before and 6 weeks after immunotherapy, and disease progression	the diversity of TCR repertoire and sin-gletons in the TCRβ pool increased after immunotherapy
LUAD	[277]	Temporal heterogeneity	Circulating TCR repertoire	Peripheral blood samples	Higher baseline circulating TCRB diversity was associated with better prognosis
MEL in mouse model	[278]	Temporal heterogeneity	TCR repertoire	tumor, draining lymph node (dLN) and peripheral blood samples	The chemotherapeutic agents for advanced lung cancer do not affect adaptive immune function over the first few treatment cycles
CRC	[279]	Spatial heterogeneity and temporal heterogeneity	Immunoscore (derived from the CD3 + /CD8 + T cell densities)	Spatiotemporally distinct sites of metastases	High immunoscore is associated with the lowest recurrence risk

BC Breast cancer, CC Cervical cancer, CRC Colorectal cancer, ESCC Esophageal squamous cell carcinoma, GBM Glioblastoma multiforme, GC Gastric cancer, HCC Hepatocellular carcinoma, LC Lung cancer, LUAD lung adenocarcinoma, MEL Melanoma, NPC Nasopharyngeal carcinoma, NSCLC non-small cell lung cancer, OC Ovarian cancer, PC Pancreatic cancer, RCC Renal cell carcinomas



### **dMMR/MSI facilitates immunotherapy through a pre-existing immunoreactive microenvironment**

In a recent meta-analysis covering 14 studies, immune checkpoint inhibitors showed encouraging potential in multiple cancer types with dMMR/MSI [81, 82]. While combining Nivolumab with CTLA-4 blockade Ipilimumab exhibits a robust response and improved efficacy [83]. Many other studies have also demonstrated the positive value of dMMR/MSI for immunotherapy, as shown in Table 4. To explore the underlying mechanism, first we need to understand the foundation of effective immunotherapy, which includes: effective antigen presentation by antigen-presenting cells (APC), followed by continuous activation and infiltration of T cells to construct a positive immune microenvironment. In cancer patients without treatment, CD8+ TILs specific to ubiquitously expressed tumor antigens manifest as a dysfunctional phenotype [66]. Immunotherapy triggers the reactivation of the immune system, giving it the ability to identify and react to neoantigens and revitalizing the cytotoxic effect of the pre-existing TIL clonalities [65, 84, 85]. Another premise is sufficient IFN- $\gamma$  production and responsive IFN- $\gamma$  signaling. Through this IFN- $\gamma$  subsequently induces an anti-tumor immune response through: (1) upregulation of antigen processing molecules, MHCII and antiangiogenic chemokines (2) recruitment of T cells and other immune cells (3) direct antiproliferative and pro-apoptotic effects [86, 87]. As for ICB, an additional condition is the upregulation of the target immune checkpoint. Continuous IFN- $\gamma$  exposure induces upregulation of immune checkpoints including PD-L1, CTLA-4, IDO and LAG-3 [87–91], of which the immunosuppressive effect is abrogated and only positive factors come into play in the context of ICB therapy (Fig. 3).

Regardless of origin and type [59], dMMR/MSI tumors are susceptible to immunotherapy owing to: (1) high TMB (2) high TIL in both tumor and tumor-adjacent tissues [59, 92] (3) upregulation of PD-1 and IFN- $\gamma$  signatures (PD-L1, CTLA-4, LAG-3 and IDO) representing an adaptive resistance to the immunoreactive microenvironment induced by MSI [5, 6]. All these three aspects are positive predictive markers [57, 93–95] of which TMB could be considered as the initiating factor. Both cancers with the strongest response to PD-1 blockade have a high degree of mutation, including lung cancer and melanoma [3, 4, 57, 96]. In addition, TMB significantly contributes to a sustained clinical benefit from CTLA-4 blockade in melanoma [97]. With a high mutation load and increased immunogenicity, dMMR/MSI tumors possess abundant infiltration with activated CTL and Th1. They have high expression of cytotoxic genes encoding IFN- $\gamma$ , signal transducers and activators of transcription 1 (STAT1), interferon regulatory factor 1 (IRF1) and IL18

[5, 98], and more frequent apoptosis of neoplastic cells attributed to both high TIL and intrinsic genetic instability [99]. Higher TIL grade is shown to be associated with better outcomes in different tumor types, including melanoma and CRC [100–102], and intrinsically linked to the response against immune checkpoint inhibitors [103–105]. Despite enhancing tumor immunogenicity, mutator phenotypes with upregulated immune checkpoints could also favor immune evasion and counterbalance the pre-existing anti-tumor immune microenvironment, particularly given the IFN- $\gamma$ -induced adaptive response. Nevertheless, upregulated immune checkpoints provide targets for ICB to re-invigorate the immune response. In addition, mutations of KRAS and TP53, although not prevalent in MSI tumors, and respectfully favor tumor proliferation and deregulate DNA repair [106–108], TP53 mutation was found to increase expression of immune checkpoints, effector T cells and IFN- $\gamma$  signature; furthermore, TP53/KRAS co-mutated subgroup manifested increased expression of PD-L1 [109, 110]. Together they may serve as potential predictive biomarker for immunotherapy. Further, WRN dependency was found to be associated with resistance to immunotherapy, in other words, WRN inhibitor may be synergic with immunotherapy, as it increases the genetic instability, and modulates the neoantigen landscape to enhance immune response [40]. Another underlying mechanism facilitating immunotherapy may be higher microvessel density (MVD) found in dMMR/MSI tumors [92], which enables increased lymphocyte extravasation. However, considering angiogenesis benefits for tumor growth, an in-depth study on MVD and MSI is highly recommended.

### **ICB**

ICB is one of the most promising anti-tumor immunotherapies to this day. The two most promising targets are CTLA-4 and the interaction of PD-1 and PD-L1. Upregulation of these immune checkpoints is an adaptive resistance associated with poor prognosis [111] and actually represents a strong pre-existing anti-tumor response, based on which ICB is applied to re-invigorate the immune response [57, 112, 113]. dMMR/MSI has been found to promote ICB efficacy in multiple tumor types, including glioblastoma multiforme [114], urothelial tract cancer [115], melanoma [57, 97], endometrial cancer [59], non-small cell lung cancer (NSCLC) [57, 112] gastric cancer [116] (Table 4).

It is believed that oligoclonal expansion of the TIL repertoire is a symbol of low TCR affinity and T cell exhaustion [117], while an appropriate level of TIL heterogeneity may be the foundation of ICB and ACT [118]. In this scenario, ICB could rejuvenate the TCR repertoire extensively rather than focusing only on several


**Table 4** Biomarkers predicting better response to immunotherapy

Biomarker status	Tumor type	N	Immunotherapy	OS (rate)	PFS (rate)	ORR/Impact	References
dMMR/MSI	CRC, non-CRC (ampullary or cholangiocarcinoma, endometrial, small bowel, gastric)	11, 9, respectively	Pembrolizumab	40%	~5 months (20 weeks); 78%	More responsive	[59]
dMMR/MSI	mCRC	74	Nivolumab	31%	12 months: 50%	Durable response and disease control	[81]
dMMR/MSI	mCRC	119	Nivolumab + Ipilimumab	55%	9 months and 12 months: 76% and 71%, respectively	Durable response and improved efficacy	[83]
dMMR/MSI	Recurrent GBM	21	Nivolumab	NA	NA	Initial and durable response	[114]
dMMR/MSI	Advanced, metastatic MSHH/dMMR CRC	61 in cohort A, 63 in cohort B	Pembrolizumab	mOS: 31.4 months and NR	mPFS: 2.3 months and 4.1 months	33% (95% CI 21–46%) and 33% (95% CI 22–46%)	[280]
dMMR/MSI	27 types of non-CRC	233	Pembrolizumab	mOS:23.5 months	mPFS: 4.1 months	34.3% (95% CI, 28.3–40.8%)	[281]
dMMR/MSI	CRPC	11	Anti-PD-1/PD-L1	NA	NA	Durable clinical benefit: 45.5%	[282]
dMMR/MSI	mCRC	307	Pembrolizumab	NR	mPFS: 16.5 months	Longer progression-free survival	[283]
dMMR/MSI (loss of h MSH2 and MSH6)	Chemo-resistant urothelial tract cancer	1	Durvalumab	NA	NA	Complete remission	[115]
dMMR/MSI, high TMB (> 37–41 mutations/Mb)	mCRC	22	Pembrolizumab, Nivolumab, Ipilimumab, Durvalumab/Tremelimumab	NA	mPFS:> 18 months,	Objective response	[95]
dMMR/pMMR, higher percentages of mucin and PD-L1 expression	mCRC	26	Pembrolizumab	NA	NA	Clinical benefit	[195]
Higher TMB	Metastatic melanoma	64	Ipilimumab or Tremelimumab	mOS: 4.4 years	NA	Durable clinical response	[97]
Higher TMB	NSCLC	28/22	Anti-PD-1/PDL1 therapies	NA	mPFS: NR/mPFS: 2.9 months	ORR: 39.3%/ORR: 9.1%	[284]
Higher IFN-γ signature (IFN-γ, STAT1, CXCL9, CXCL10, IDO, MHCII HLA-DRA, LAG-3)	Metastatic melanoma, GC, HNSCC	81,33,40	Pembrolizumab	NA	NA	Higher response rate	[182]
Higher IFN-γ signature (IFN-γ, PD-L1, LAG-3 and CXCL9)	NSCLC	30	Durvalumab	Longer OS	Longer mPFS	Higher response rate	[137]

**Table 4** (continued)

Biomarker status	Tumor type	N	Immunotherapy	OS (rate)	PFS (rate)	ORR/Impact	References
Higher IFN-γ signature (LAG-3, PD-L1, IDO) and TIL	mCRC	19	Pembrolizumab	NA	NA	Higher response rate	[196]
Higher IFN-γ signature and PD-L1 expression	Urothelial carcinoma	265	Nivolumab	mOS:7 months	NA	ORR:28.4% with PD-L1 expression of 5% or greater, 23.8% with PD-L1 expression of 1% or greater, 16.1% with PD-L1 expression of less than 1%	[134]
Higher PD-L1 expression and TMB	Metastatic urothelial carcinoma	310	Atezolizumab	NA	NA	Significantly improved ORR	[113]
Higher PD-L1 expression and TMB	Solid tumors across 22 types	> 300	Pembrolizumab	NA	Longer PFS	Stronger objective response rate	[285]
PD-L1 positive	SCLC, melanoma or RCC	296	Nivolumab	NA	NA	Complete/partial response	[57]
PD-L1 positive	Melanoma, NSCLC, RCC, CRC, CRPC	41	Nivolumab	NA	NA	Objective response and clinical benefit	[112]
Higher IDO expression and TIL	Advanced melanoma	82	Ipilimumab	NA	NA	Better clinical outcome	[135]
INCR1 knockdown	Mice tumor models	-	CAR-T cell therapy	NA	NA	Enhanced T cell infiltration, significantly reduced tumor growth	[130]

OS Overall survival, PFS Progression-free survival, ORR Overall response rate, dMMR Mismatch repair deficient, MSI Microsatellite instability, CRC Colorectal cancer, mCRC Metastatic colorectal cancer, GBM Glioblastoma multiforme, CRPC Castration-resistant prostate cancer, NSCLC Non-small cell lung cancer, GC Gastric cancer, HNSCC Head and neck squamous cell carcinoma, SCLC Small cell lung cancer, RCC Renal cell cancer, Pembrolizumab PD-1 blockade, Nivolumab PD-1 blockade, Ipilimumab CTLA-4 blockade, Durvalumab PD-L1 blockade, Tremelimumab CTLA-4 blockade, Atezolizumab PD-L1 blockade, CAR-T cell Chimeric antigen receptor-T cells, NA Not available, mOS Median overall survival, mPFS Median progression-free survival



T cell epitopes, resulting in more T cells responding to ubiquitous neoantigens, enhancing overall immune competence in the anti-tumor response and leading to most clinically significant responses [119, 120]. Additionally, CD4+ T cells that stimulate and suppress the immunity of CD8+ T cells coexist in the tumor microenvironment [121]. While Tregs are regarded as suppressive regulators in tumor immunology and a biomarker of poor prognosis [122], they still possess specific reactivity against tumor antigens, facilitating CTLA-4 therapy [123]. Although

PD-1 indicates negative regulatory function and exhaustion of peripheral T cells induced by the PD-1 signaling pathway and may contribute to the decreased diversity of T cell repertoire [124, 125], CD8+ T cells may function efficiently after PD-1 immunotherapy [126, 127]. Therefore, even though TILs are considered an immunosuppressive phenotype, they possess substantial capacity to induce a cytotoxic effect against tumor cells and their potential proliferation [121].

Among the various cytokines, IFN- $\gamma$  is the main factor that induces upregulation of PD-L1 [128]. JAK1/2–STAT1/2/3–IRF1 pathway is the most important signaling cascade that is involved [129]. When IFN- $\gamma$  binds to its receptors interferon-gamma receptor 1/2 (IFNGR 1/2), it increases the level of IFN-stimulated noncoding RNA 1 (INCR1)—a major regulator of IFN- $\gamma$  signaling by modulating post-transcriptional JAK expression [130]. The subsequent activation of JAK1/2 leads to phosphorylation and dimerization of the downstream signal transducers and activators of transcription (STATs). Then the downstream transcription factors IRFs bind to their response elements IRF-1 response elements 1/2 (IRE1/2) in the upstream 5'-flanking region of the PD-L1 gene promoter [131] and induce PD-L1 upregulation (Fig. 3). A positive correlation between IRFs and PD-L1 mRNA expression was found in hepatocellular carcinoma (HCC) [131]. Similar to PD-L1, the expression of CTLA-4 in human melanoma cells is also regulated by IFN- $\gamma$  through the JAK1/2-STAT1-IRF1 pathway [132]. CTLA-4 induces antiproliferation of T cells, Tregs activation and upregulation of IDO [133], playing a negative role in anti-tumor immune response. Therefore, anti-CTLA-4 therapy is utilized to increase the ratio of effector T cells to Tregs [87], and, in turn, upregulate IFN- $\gamma$  production. Higher expression of PD-L1 and IDO predicts a superior response to PD-1 blockade and CTLA-4 blockade (ipilimumab), respectively [57, 134, 135], emphasizing the role of IFN- $\gamma$ -induced IDO in immune checkpoint blockade therapy. Additionally, IFN- $\gamma$  can induce MHCII expression, which is correlated with multiple important prognostic pathways and better overall survival rate [58]. In melanoma, MHCII expression is a predictor for anti-PD-1 and anti-PD-L1 response [136]. Altogether, high expression of IFN- $\gamma$  signaling indicates long-term benefits from ICB [89, 116, 137]. In line with the relationship between PD-L1, CTLA-4, IDO and immunotherapy discussed herein, targeting LAG-3 strongly stimulates CD8+ T cell infiltration and IFN- $\gamma$  secretion [138, 139], suggesting the possibility of an alternative immunotherapy. Interestingly, blockade of a single immune checkpoint could lead to upregulation of others [140]. For example, inhibition of LAG-3 improves the efficacy of PD-1 blockade in several mouse cancer models [141–144], indicating the better efficacy of combinatorial ICB.

#### **ACT**

Efficacy of targeting a ubiquitous tumor antigen in adoptive cell therapy has been demonstrated [145]. Specific TCR-transduced T cells are clinically effective in treating patients with metastatic synovial sarcoma [7], while exploiting TILs to recognize multiple tumor neoantigens

is effective in single-patient studies on several tumors [70]. Targeting several tumor antigens is an ideal scenario, which circumvents tumor escape mechanisms such as tumor heterogeneity and constructs a focused TIL repertoire against tumor cells [146].

However, the bottleneck of ACT is unable to address T cell migration and abnormal function at tumor sites. A recent study showed that PD-1 expression on transferred T cells could be induced by tumor environment [147], indicating that downregulation of immunosuppressive factors and silencing IFN- $\gamma$  signaling to weaken PD-1-PD-L1 interactions may help improve potency. INCR1 knockdown cells are more susceptible to cytotoxic T cell-mediated death compared to controlled cells [130]. However, PD-1 blockade could improve therapeutic efficacy of ACT by enhancing T cell proliferation of T cells and upregulating IFN- $\gamma$  [147, 148]. Importantly, functional IFN- $\gamma$  signaling could induce chemokine (C-X-C motif) ligand 10 (CXCL10) to recruit more activated T cells and trigger a positive feedback loop [147] (Fig. 3). In addition, PD-1 blockade could increase the activation and proliferation of CAR-T cells in vitro and regress tumor growth in vivo through enhancing their anti-tumor effect and reducing myeloid-derived suppressor cells at tumor sites [149]. Noteworthy, a recent study also revealed that recurrent melanoma after ACT treatment exhibited high expression of IFN- $\gamma$  signaling (PD-1, PD-L1, CTLA-4, though the picture was heterogeneous), which provided tractable targets for salvage immunotherapy, and indeed allowed for effective ICB [150]. As mentioned, IFN- $\gamma$  plays an intricate role in ACT. ACT treatment outcomes are different when combined with other therapies due to the heterogeneity of IFN- $\gamma$  signaling.

#### **Vaccination with dMMR/MSI-induced antigens**

MMR-deficient subclones progress to manifest dMMR/MSI cancer lesions despite strong immunogenicity and immune surveillance due to upregulation of immune checkpoints and mutations favoring immune evasion. ICB remarkably benefits outcomes of dMMR/MSI tumors; in non-responders, combined with other immune-supportive approaches, it is expected to turn “cold” tumors into “hot” ones and improve the response rate. dMMR/MSI triggers frequent generation of frameshift mutations and gives rise to highly immunogenic frameshift-derived peptides (FSP), which contain multiple immunologically relevant neoepitopes [151]. These neoantigens are tumor-specific and shared by most MSI tumors [152]. A vaccine based on these neoantigens could be designed to prevent outgrowth of undetected dMMR/MSI subclones in pMMR tumors. A clinical Phase I/IIa trial found three commonly mutated FSPs (derived from genes AIM2, HT001 and TAF1B

(NCT01461148), of which 98.5% of all MSI CRCs harbor at least one mutation [152]. Theoretically, immune response directed against FSPs can be induced in the majority of MSI CRCs, and the study results confirmed that this FSP vaccination was well tolerated and consistently induced immune responses [153]. The latest research analyzed 320 MSI tumors and selected 209 FSPs to generate a vaccine referred to as Nous-209. The vaccine induced IFN- $\gamma$ +FSP-specific T cells in vaccinated mice and exhibited strong immunogenicity [154]. Its safety, tolerability and immunogenicity are currently under clinical evaluation in mCRC, gastric and gastroesophageal cancer patients in combination with Pembrolizumab (NCT04041310) (Table 5). Vaccination with frameshift-derived neoantigen-loaded DC is also under investigation in MSI CRCs and persons who are known to harbor germline MMR gene mutation but without diseases yet (NCT01885702). Despite the therapeutic implications for MSI tumors, this trial could also explore the preventive significance of FSP vaccine for people with MMR mutations. Of note, a vaccine targeting these FSP antigens could broadly eliminate dMMR/MSI tumor cells despite the ITH and rapid tumor evolution, since these mutations are driver events at early stage of tumorigenesis [155, 156] (Fig. 3). Moreover, an IDO-derived peptide vaccine activates IDO-specific T cells which recognize and kill both tumor cells and immunosuppressive dendritic cells in vitro, significantly improving overall survival in III/IV NSCLC patients [157]. As combination therapy may have a synergistic effect due to distinct mechanisms of action, clinical trials are also underway to combine IDO and PD-L1 peptide vaccine with PD-1 blockade to treat metastatic melanoma (NCT03047928). Vaccines based on other upregulated antigens in dMMR/MSI tumors warrant further investigation.

When developing vaccines, a suitable vehicle of transmission can greatly enhance the therapeutic effect. Nanoparticles have been the promising vehicle of vaccine. They are endowed with outstanding physiochemical properties, such as high tissue specificity, manageable surface chemistry and big specific surface area [158]. The nanoparticles can be the vehicle of certain bioactive substance such as PD-L1 inhibitory peptide [159], or be developed with certain features to cause damage to tumor cells [160]. A latest review summarizes two main mechanisms that contribute to the anti-tumor effects of immunotherapy based on nanotechnology: one is to elicit an efficient immune response against tumor during tumorigenesis, while the other is to turn the “cold” immune-suppressive tumor microenvironment into a “hot” immune activated [158].

When exploring treatments for tumor, components of TME such as macrophages, fibroblasts or even tumor

vasculature and tumor-draining lymph nodes can be targets of nanoparticles [161]. A vaccine was designed to deliver antigenic microparticle, which transformed tumor infiltrated macrophages into a tumor-suppressive M1 phenotype, and activated strong host immune response against tumor [162]. To enhance the specificity of nanoparticles, particular conditions are used to stimulate the function of the materials. A type of supra-molecular gold nanorods can be activated by the second near-infrared-window (NIR-II) light. The nanorods are designed to be the vehicle of CRISPR/Cas9, and they can disrupt PD-1 gene expression of the tumor cells and facilitate immunogenic cell death when irradiated by NIR-II laser [163]. Some other nanoparticles can be released from membrane when entering a microenvironment with specific pH. A short interfering RNA named siFGL1 delivered by nanoparticles with hybrid biomimetic membrane can efficiently silence the FGL1 gene, which is triggered by pH [164]. Whether employed independently or in combination with other immunotherapies as adjuvant, these nanomaterials can enhance immune responses and exhibit anti-tumor efficacy [160, 164].

#### **dMMR/MSI fuels ITH and also correlates with resistance to immunotherapy**

Despite improved efficacy in dMMR/MSI tumors, reported response rates to ICB are variable and often <50% [95]. What differentiates responders from non-responders? As discussed above, intratumor heterogeneity caused by dMMR/MSI can be a determinant factor leading to the unfavorable response and poor prognosis.

#### ***ITH impairs the quality of TIL response and impedes immunotherapy***

Although more diversified intratumoral TCRs may be generated in the context of dMMR/MSI, they are not always associated with better clinical outcome [65, 66]. It has long been recognized that tumor progression is accompanied by an increase in tumor mutation load, and the inevitable generation of tumor neoantigens [165]. High ITH is connected to tumor progression and resistant to therapies in many cancer types [47]. Heterogeneity in tumor antigen and immune cells is also significant among melanoma metastases, which leads to different responses to immunotherapy [166]. Excessive expression of subclonal neoantigens may lead to the relatively low expression levels of neoantigens, and T cells may be unable to encounter and activate against those low-frequency neoantigens [167]. Moreover, TCR repertoire diversity is associated with inadequate expansion of TCR clones and deficient infiltration into tumors, which may result from the immunosuppressive state of T cells caused by T cell

**Table 5** Ongoing clinical trials investigating immunotherapy in dMMR/MSI tumors

Study group	Trial design	Phase	Current status	NCT number
MSI GIC	Immunotherapy during the perioperative treatment stage	–	Not yet recruiting	NCT04640103
MSI mCRC	At least one administration of PD-1 blockade	–	Recruiting	NCT04612309
MSI locally advanced RC	PD-1 blockade + neoadjuvant chemoradiotherapy (capecitabine plus irinotecan)	II	Not yet recruiting	NCT04411524
MSI mCRC	Avelumab in the 2 <sup>nd</sup> line versus standard chemotherapy ± targeted therapy	II	Recruiting	NCT03186326
MSI mCRC	Modified mFOLFOX6/bevacizumab plus atezolizumab versus single agent atezolizumab	III	Recruiting	NCT02997228
MSI CRC	Nivolumab + Ipilimumab + Radiation therapy	II	Recruiting	NCT03104439
MSI NSCLC, SCLC, UC, HNSCC, MCC, melanoma, RCC, GC, cervical cancer, HCC, CRC	PD-1/PD-L1 blockade + N-803	IIb	Recruiting	NCT03228667
MSI mCRC, READ, other metastatic solid tumors	PD-L1 blockade + TGFbetaRIII fusion protein (M7824)	Ib/II	Recruiting	NCT03436563
mCRC	Vaccination with frameshift-derived neoantigen-loaded DC	I/II	Active, not recruiting	NCT01885702
MSI solid tumors	Nivolumab + Relatlimab	II	Recruiting	NCT03607890
MSI localized oesogastric-gastric cancer	Neoadjuvant nivolumab + ipilimumab	II	Recruiting	NCT04006262
MSI advanced solid tumors	FT500 + Nivolumab + Pembrolizumab + Atezolizumab +	I	Recruiting	NCT03841110
Advanced GIC	Pembrolizumab + Wnt inhibitor CGX1321	I	Recruiting	NCT02675946
Advanced dMMR/MSI CRCs	Ipilimumab, nivolumab, oxaliplatin, leucovorin, fluorouracil, irinotecan, bevacizumab, cetuximab	III	Recruiting	NCT04008030
Advanced cancers	NBTR3 + radiotherapy + PD-1 blockade	I	Recruiting	NCT03589339
dMMR/MSI locally advanced CRCs	Toripalimab + chemoradiotherapy	II	Not yet recruiting	NCT04301557
dMMR/MSI locally advanced or mCRCs	IBI310 + sintilimab	II	Active, not recruiting	NCT04258111
dMMR/MSI CRC, GC and gastro-esophageal junction (G-E junction) tumors	Nous-209 Genetic Vaccine	I	Active, not recruiting	NCT04041310
dMMR/MSI locally advanced RC	Sintilimab ± chemoradiotherapy	II/III	Recruiting	NCT04304209
dMMR/MSI EC, CRC, GC	Neoadjuvant Pembrolizumab	II	Not yet recruiting	NCT04795661
Locally advanced dMMR/MSI CRC	Camrelizumab + Apatinib	II	Recruiting	NCT04715633
dMMR/MSI CRC	Neoadjuvant <i>Toripalimab</i> ± Celecoxib	I/II	Recruiting	NCT03926338
dMMR/MSI distal RC	Evaluate the effect and safety of watch and wait in patients accessed pCR after PD-1 monoclonal antibody therapy	NA	Recruiting	NCT04643041
MSI resectable GC/GEJC	Neoadjuvant/definitive treatment of Tremelimumab and Durvalumab	II	Recruiting	NCT04817826
Recurrent and metastatic MSI and non-MSI CRC	Ipilimumab, Nivolumab, Daratumumab, LAG-3 blockade	II	Active, not recruiting	NCT02060188
dMMR/MSI solid tumors	N803 + PD-1/PD-L1 blockade	IIb	Active, not recruiting	NCT03228667
Metastatic/locally advanced/unresectable dMMR/MSI solid tumors	Pembrolizumab + Pevonedistat	I/II	Recruiting	NCT04800627
dMMR/MSI locally advanced <i>READ</i>	Neoadjuvant Nivolumab + Ipilimumab + short-course radiation	II	Recruiting	NCT04751370
dMMR/MSI locally advanced solid tumors	Neoadjuvant Pembrolizumab	II	Recruiting	NCT04082572
dMMR/MSI mCRC	Third-line AlloStim immunotherapy	II	Not yet recruiting	NCT04444622
Metastatic melanoma	Nivolumab + peptide vaccine consisting of PD-L1 and IDO	I/II	Recruiting	NCT03047928


GIC Gastrointestinal cancer, mCRC Metastatic colorectal cancer, RC Rectal cancer, NSCLC Non-small cell lung cancer, SCLC Small cell lung cancer, HNSCC Head and neck squamous cell carcinoma, UC Urothelial cancer, MCC Merkel cell carcinoma, RCC Renal cell carcinoma, GC Gastric cancer, HCC Hepatic cell carcinoma, READ rectal adenocarcinoma, GEJC Gastro-esophageal junction cancer, EC endometrial cancer, Avelumab PD-L1 blockade, mFOLFOX6 Fluorouracil plus leucovorin calcium and oxaliplatin, N-803 Super antagonist of IL-15, Relatlimab LAG-3 blockade, FT500 Induced pluripotent stem cells (iPSC)-derived NK cell cancer immunotherapy, NBTR3 Nano tumor radiotherapy sensitizer, Toripalimab PD-1 blockade, IBI310 CTLA-4 blockade, Sintilimab PD-1 blockade, Camrelizumab PD-1 blockade, Apatinib VEGF inhibitor, Celecoxib Cyclooxygenase inhibitor, Daratumumab MEK inhibitor, Pevonedistat NEDD8-activating enzyme, NA Not available

exhaustion, low TCR affinity, etc. [168, 169]. A higher degree of TCR ITH and consequent clonotypes with low frequencies were revealed in different kinds of tumors and were linked with unfavorable prognosis [65, 170, 171]. Besides, some TILs have lost their functions owing to other dysfunction during the process of immune response. For instance, the tumor antigen TILs previously recognized can be depleted following immunoeating [172, 173], and deprivation of the presenting MHC allele can disrupt antigen presentation [174, 175] (Fig. 4). Therefore, same as above, heterogeneity in the quality of T cell responses, instead of the quantity, may be a determinant factor in anti-tumor response [65].

**Impact of IFN- $\gamma$  signaling heterogeneity on immunotherapy**

Provided that IFN- $\gamma$  signaling displays a degree of heterogeneity and its downregulation correlates with an acquired resistance phenotype, alterations of essential components within IFN- $\gamma$  signaling pathways could modify therapeutic efficacy. Recent studies demonstrate that INCR1 is transcribed as an antisense RNA from the PD-L1/PD-L2 locus and knockdown of INCR1 decreases PD-L1 expression [130]. JAK1/2-deficient cells emerged under/after ICB in patients with advanced melanoma and

obtained resistance to PD-L1 blockade, which may result from pre-existing heterogenous subclones or through an adaptive response [9, 176, 177]. JAK loss is possibly correlated with lack of T cell infiltration based on the findings that factors downstream of JAK1/2 controls chemokines with chemoattractant effect on T cells, such as CXCL9, CXCL10 and CXCL11 [113, 178]. Also, high expression of PD-L1 significantly correlates with an objective response to PD-L1 blockade compared to PD-L1 negative patients [112, 113]. Altogether, dysfunction of IFN- $\gamma$  signaling leads to the lack of PD-L1 expression, resulting in off-target of PD-L1 blockade, and less T cell infiltration for an anti-tumor effect (Fig. 4). Consistent with what's described above, an interesting study mixed IFN- $\gamma$ -insensitive tumor cells of melanoma with wild type (WT) tumor cells to mimic ITH. IFN- $\gamma$ -insensitive cells finally grow out in the context of anti-PD-L1 therapy as a result of (1) failure to activate positive immune response by IFN- $\gamma$  (2) lack of PD-L1 upregulation as the treatment target (3) immunodepressive microenvironment because of PD-L1 provided by WT. Moreover, IFN- $\gamma$  could push the tumor further toward the IFN- $\gamma$ -insensitive cells [179].



**Fig. 4** Negative effect of ITH in MSI tumor under immunotherapy. **a** In MSI tumors, hyperactivation of WNT/ $\beta$ -catenin signaling suppresses effector T cells function by reducing IFN- $\gamma$ . Mutations in JAK and STAT result in impaired IFN- $\gamma$  signaling and lack of induced MHC class I expression. Moreover, JAK1/2 controls chemoattractant such as CXCL9, CXCL10 and CXCL11, and mutations in JAK1/2 cause lack of downstream T cell infiltration.  $\beta$ 2M gene mutations lead to impaired MHC class I function and knockdown of INCR1 decreases PD-L1 expression. Dysfunction of IFN- $\gamma$  signaling results in lack of PD-L1 expression which leads to PD-L1 blockade out of target, and defective migration of adoptive T cells into tumors in melanoma thereby reducing the efficacy of ICB. **b** Appropriate level of neoantigen ITH leads to adequate TCR expansion, sufficient infiltration and high TCR affinity, which lead to cytotoxic effects of immunotherapy. In the other hand, excessive expression of neoantigen ITH leads to inadequate TCR expansion, insufficient infiltration and T cell exhaustion, which result in inefficient immunotherapy



In addition, the JAK mutation contributes to the primary resistance to anti-PD-1 therapy in patients with advanced melanoma and colon cancer despite having a high mutation load [59, 96, 180, 181]. In previous studies, copy number alterations (CNAs) and single-nucleotide variants (SNVs) of IFN- $\gamma$  signaling including loss of IFNGR1/2, JAK1/2, IRF1, as well as amplification of important IFN- $\gamma$  pathway inhibitors SOCS1 and PIAS4, were found in patients with metastatic melanoma resistant to anti-CTLA-4 therapy. In addition, CXCL10 is reduced compared to the IFN- $\gamma$  responsive cells [177]. Moreover, the heterogeneity of MHC expression on tumor cells and its lack of coordination with IFN- $\gamma$  signaling have a significant impact on ICB. In sum, expression of IFN- $\gamma$  strongly correlates with the response to ICB [182] and has validated in several studies. Deficiency of IFN- $\gamma$  signaling can weaken the effect of positive immunoregulation in multiple aspects, thereby reducing efficacy of ICB. Diverse subclones carrying heterogenous IFN- $\gamma$  signaling within tumors have an impact on drug response and should be considered when selecting therapeutic regimens. Given that CTLA-4 blockade leads to increased production of IFN- $\gamma$  and thereby upregulating PD-L1, combination with PD-L1 blockade could make a better clinical response; and combination with new immune-related targets needs to be studied unremittingly in the future.

Mutations in JAK and STAT result in impaired IFN- $\gamma$  signaling, lack of induced MHC class I expression, as well as inhibition of the WNT signaling pathway [11, 183].

A study investigating immune evasion in 1,211 CRC patients found that non-responsive dMMR/MSI patients frequently underwent immunoediting through upregulated WNT/ $\beta$ -catenin signaling and complete disruption of key genes in the antigen presentation pathway [7, 8]. High WNT signaling with mutations of  $\beta$ -catenin is inversely correlated with TIL independent of high TMB in melanoma and CRC, thereby reducing the efficacy of ICB [7, 184]. Other studies found that hyperactivation of WNT/ $\beta$ -catenin signaling suppressed effector T cells function by reducing IFN- $\gamma$  [185] and led to defective migration of adoptive CD8+T cells into tumors in melanoma [186]. This indicates that WNT signaling inhibitors may reverse immune evasion to facilitate immunotherapy. Approximately 30% of dMMR/MSI CRC display gene alterations of  $\beta$ 2 microglobulin ( $\beta$ 2M) in that the  $\beta$ 2M gene harbors four coding microsatellites (cMS) [152].  $\beta$ 2M gene mutations lead to impaired MHC class I function, defective recognition and presentation of neoantigens which render the immune evasion from immunotherapy [176, 187, 188]. Altogether, mutations of IFN- $\gamma$  signaling, WNT/ $\beta$ -catenin signaling and antigen presentation machinery, followed by resistance to T cell-induced death could all trace back to dMMR/MSI-induced heterogeneity (Table 6) (Fig. 4). Although high TMB is discussed as a positive predictor of immunotherapy, the quality of mutations to generate a robust T cell response may outweigh the quantity.

**Table 6** Underlying mechanisms of resistance to immunotherapy

Findings	Tumor type	N	Immunotherapy	Impact	References
LOH in $\beta$ 2M	Metastatic melanoma	160	Ipilimumab, Pembrolizumab	No response	[188]
Deficient IFN- $\gamma$ pathway genes (IFNGR1, IRF1, JAK2 and IFNGR2)	Melanoma	16	Ipilimumab	No response	[177]
Loss-of-function mutations in JAK1/2, inactivation of $\beta$ 2M	Metastatic melanoma	4	Pembrolizumab	Initial response followed by progression	[176]
Gain-of-function mutations in $\beta$ -catenin	Metastatic melanoma	266	anti-PD-L1/anti-CTLA-4	Absence of T cell infiltration	[184]
Active $\beta$ -catenin expression	Melanoma model	–	ACT	No response, resistant to memory CD8+T Cells	[186]
Biallelic losses of $\beta$ 2M and HLA genes, upregulated WNT/ $\beta$ -catenin signaling	CRC	179	–	Absence of T cell infiltration	[7]
Increased Wnt signaling, decreased IFN- $\gamma$ levels	Melanoma	31	–	Suppression of induction and effector phases of anti-tumor T cell responses	[185]
Loss-of-function mutations in JAK1/2	Melanoma	169	Anti-PD-L1/anti-CTLA-4	Progressive disease	[9]
Loss-of-function mutations in JAK1/2	Metastatic melanoma, CC	39	Anti-PD-1	No response	[180]

LOH Loss of heterozygosity, IFN- $\gamma$  Interferon-gamma, IFNGR1/2 Interferon-gamma receptor 1/2, IRF1 Interferon regulatory factor 1, JAK1/2 Janus kinase 1/2, HLA Human leukocyte antigen, CRC Colorectal cancer, CC Colon cancer, ACT Adoptive cell transfer

### Status of MMR system and microsatellite exhibits heterogeneity to some extent

In sporadic CRC cases, which arise from epigenomic silencing by hypermethylation of the MMR gene promoter, MMR deficiency may occur during tumor progression and display tumor heterogeneity (Fig. 1). In 100 cases of sporadic colon cancers, discordance was discovered when IHC and PCR-based microsatellite evaluation were performed in two different areas from the same tumor tissue in 8 cases, of which 6 cases presented normal MMR protein expression but exhibited MSI and 2 cases were the opposite [189], indicating the ITH of dMMR/MSI. In addition, cases reported a coexistence of dMMR and pMMR subclones in the primary lesions of mCRC and prostate cancers, but only pMMR/MSS was detected in the metastatic lesions [190, 191]. dMMR/MSI tumors are less likely to metastasize to regional lymph nodes and distant organs [1, 6] because (1) tumor cells with enhanced antigenicity are more likely to be recognized and localized (2) accumulated DNA damage results in decreased cell viability [192, 193]. There are also some studies verifying the heterogeneity of MSI and MMR protein expression [190, 194]. During the treatment, residual pMMR/MSS cells emerge from mixed subclones and foster temporal heterogeneity, resulting in acquired resistance. Therefore, due to the predictive and therapeutic value of dMMR/MSI, early detection of resistance and targeting the minimal resistant subclones is imperative.

### Combined predictive markers are important to guide precise and personalized immunotherapy

dMMR/MSI, TIL and IFN- $\gamma$  signaling can altogether reflect the response to immunotherapy. However, there is a disparity between response rate and detected biomarker status. Schrock et al. found the optimal cutoff for TMB as 37–41 mutations/Mb, below which the response to anti-PD-1 monotherapy was inferior despite dMMR/MSI status [95]. This number could be lower with combined ICBs [81], suggesting that combined therapy is preferred to monotherapy for dMMR/MSI patients with TMB below the cutoff. Although pMMR/MSS CRCs account for the majority of total number of CRCs and have a very low response rate to ICB [59], recent studies demonstrated that a subgroup of pMMR mCRC patients also obtained clinical remission from ICB due to higher level of IFN signature (PD-L1, LAG-3, IDO) [195, 196]. Some PD-L1 negative patients also responded to ICB [113, 134] probably due to sampling bias as a result of spatial heterogeneity, or other undetected factors. As discussed above, these markers alone do not predict therapeutic efficacy perfectly on an individual basis, but

could make up for each other. Of note, all three features display a certain degree of heterogeneity. Thus, combating heterogeneity using novel detection methods and better identifying patients' anti-tumor immune capacity is the key to pre-select those most likely to benefit from treatment and spare others from unnecessary side effects (Fig. 1).

### Detection methods to combat spatial heterogeneity

The optimal treatment is expected to target the trunk of all subclone mutations and subclonal driver events [19]. Therefore, it is indispensable to overcome the spatial heterogeneity and understand the full range of tumor tissues. The key step is accurate assessment, which is supported by a wealth of progressive studies [28, 197]. The conventional detection methods for dMMR/MSI are PCR and IHC. However, detection accuracy is limited by unfaithful Taq polymerase, limited panel numbers, the necessity for matched normal tissues and experience-dependent IHC [28]. Next-generation sequencing (NGS) allows for comprehensive investigations of multiple microsatellite loci simultaneously. MSI detected by PCR and 592-gene NGS was compared across 26 cancer types and a cutoff of  $\geq 46$  altered loci was found to classify samples as MSI [198], indicating that MSI-NGS is valid across cancer types and not limited by normal tissue acquisition. Additionally, tools based on NGS including mSing [199], MSIsensor [200], MSIplus [201] and MANTIS [202] have significantly improved sensitivity and specificity.

Several breakthroughs have been made with single-cell sequencing. Tumor cell diversity is analyzed by flow cytometry through a single-cell suspension which fully represents an intact tumor, providing the highest resolution to determine the true number of heterogenous subclones and characterize them without aggregating the information from multiple cells [203, 204]. Among all technologies, transcriptome analysis—single-cell RNA sequencing (scRNA-Seq) is the most advanced [203]. scRNA-Seq sheds light on the tumor immune microenvironment by showing the proportions of TILs. In mCRC samples, proportions of CD8<sup>+</sup>T cells, Th1/2 cells and memory T cells were lower, and approximately 81.94% (118/144) of the genes related to WNT signaling were upregulated [205]. Patients with large B cell lymphoma who achieved complete response or remission showed improvement of memory T cells in scRNA-Seq of CAR-T cells [206]. Furthermore, scRNA-Seq identified TILs with high heterogeneity in Osteosarcoma (OS) and high expression of LAG-3 and TIGIT (T cell Immunoreceptor with Ig and ITIM domains) on CD8<sup>+</sup> T cells, identifying new therapeutic targets for OS [207]. scRNA-Seq could also offer TCR sequence information and provides insight into TCR rearrangements at the single-cell level,

unfolding dynamic responses to immunotherapy including vaccine and ICB [208]. TCR sequencing has been widely used and has helped probe into the dynamic combinations of T cell subsets and the spatial heterogeneity of TILs [84, 209, 210]. Single-cell sequencing has identified the heterogeneous expression of IFN- $\gamma$ -related genes including MHCII in single cells, of which higher expression drives patients' responsiveness to PD-1 blockade based on longitudinal scRNA-Seq [58, 211]. Enrichment of 227 IFN- $\gamma$ -dependent transcripts including PD-L1 and IDO was also identified across multiple tumors and could be utilized to stratify immunotherapy response [212]. Mitra et al. found that single-cell analysis of a targeted transcriptome which predicted drug responses for individual cells was able to predict the response to a proteasome inhibitor when combined with machine learning in multiple myeloma [213]. Conceivably, it could also apply to immunotherapy based on correlative transcriptome signatures. Finally, simultaneous triple omics sequencing could reveal complex interplays within genetic, epigenetic and transcriptomic levels and provide the most complete maps of tumor cell subpopulations to guide treatment options [16].

The above discussion prompted us to quantify ITH and stratify patients by classifying potential responses to immunotherapy using combined biomarkers. Studies have classified immune status of tumors into several subtypes to support decision making and facilitate response prediction, based on TIL, IFN- $\gamma$  signaling signatures and immune checkpoints expression [77, 214, 215]. Future studies should consider including multiple biomarkers to optimize this stratification method.

#### **Real-time monitoring: combat temporal heterogeneity**

Due to the temporal heterogeneity during natural tumor progressing and therapeutic interventions, it is important to achieve real-time monitoring in a minimally invasive way and promptly adjust therapeutic regimens. Longitudinal analysis of tumor-derived genetic materials including CTCs and ctDNA extracted from patients' blood has achieved promising progress across several types of solid tumors [216–219]. These materials display all the alterations present in the tumor and the metastasis, which help eliminate false results caused by spatial heterogeneity. ctDNA analysis by liquid biopsy (blood test) is feasible and has been found to be sensitive and specific in various cancer types [220–222]. Studies showed that ctDNA identified genomic profiling highly consistently with and beyond the findings of tissue biopsy [223–228]. In 433 metastatic prostate cancer cases, dMMR identification using ctDNA was highly concordant with IHC and PCR of tumor tissue. Subclonal diversity and  $\beta$ -catenin activation were detected with sensitivity as

well [229]. Detection of MSI using ctDNA with NGS in CRC was better than PCR and demonstrated high overall accuracy in pan-cancer [230]. Additionally, an initial peak following by a rapid decrease in ctDNA level indicates an early response for ACT, which in turn allows for early identification of those at risk of poor response and treatment optimization [206, 231]. Analysis of CTC also enables real-time monitoring and provides insight into the genomic profiling [232]. High expression of PD-L1 on CTC at baseline may be predictive to screen patients for PD-1/PD-L1 blockade and reduction of total CTC through longitudinal monitoring indicated a good response [233, 234]. Adjuvant PD-1/PD-L1 blockade deserves evaluation in patients whose PD-L1 (+) CTCs are detected after curative treatment [235]. The number of CTCs significantly decreased after NK cell treatment in NSCLC and liver cancer, reflecting the therapeutic efficacy with decent sensitivity [236, 237]. Moreover, overexpression of  $\beta$ -catenin was detected in melanoma CTCs, but not in healthy donor and lacking in patients with complete response to ICB [238]. TMB measured from liquid biopsy was also found to be a predictive biomarker for atezolizumab (anti-PD-L1) in NSCLC, and able to identify patients who would benefit accurately and reproducibly [239]. In aggregate, liquid biopsy is a highly sensitive and informative method that can overcome ITH to identify low-frequency alterations and enable early detection of resistance or relapse.

Moreover, imaging techniques also allow for repeated response measurements during treatment, enabling visualization of ITH. Positron-emission tomography (PET) imaging with  $^{89}\text{Zr}$ -atezolizumab (anti-PD-L1) in NSCLC, bladder and triple-negative breast cancer showed that tracer uptake was heterogeneous and corresponded to PD-L1 and IFN- $\gamma$  signaling levels at sites, appearing to be a strong predictor of atezolizumab response [240]. Radiolabeled [ $^{111}\text{In}$ ] PD-L1-mAb and near-infrared dye conjugated NIR-PD-L1-mAb also demonstrably detected graded levels of PD-L1 expression with high specificity using SPECT/CT imaging [241, 242]. Transitioning these detective methods to combat ITH from the bench to bedside and evaluate and monitor patients' potential benefits from immunotherapy is an enormous challenge that requires more clinical studies.

#### **Conclusion**

Immunotherapy has led to unprecedented long-lasting anti-tumor activity in cancer patients. Currently, clinicians utilize MSI evaluation and other methods, such as IHC of PD-L1, to distinguish those most likely to benefit. However, there are quite a few dMMR/MSI patients who do not respond to immunotherapy as expected. In this review, we explored factors facilitating or impeding

immunotherapy from a novel perspective—complex interplay of MSI and ITH. It is commonly believed, and also true, that dMMR/MSI generates subclones with heterogenous genotypes and neoantigens, which stimulate anti-tumor response through higher TIL grade and expression of IFN- $\gamma$ -related genes. The premises of effective immunotherapy—continuous activation and infiltration of T cells, sufficient IFN- $\gamma$  production and responsive IFN- $\gamma$  signaling—are satisfied in this scenario. Nonetheless, non-responders may suffer from the two-sided effects of dMMR/MSI due to a greater tendency for mutations in key elements involved in anti-tumor immunity. Additionally, excessive expression of diversified subclonal neoantigens may lead to relatively low expression of each neoantigen, resulting in inadequate expansion of TCR clones, subsequent T cell exhaustion and insufficient infiltration. Therefore, the subject boils down to one point: the quality of ITH outweighs the quantity.

To better identify patients' anti-tumor immune capacity and guide individualized immunotherapy, single-cell sequencing uncovers the heterogenous pictures of tumor at the highest resolution, while liquid biopsy achieves real-time monitoring and enables early detection of resistance. Other investigative methods combined with imaging techniques provide multiple directions of future research. The advantage of a dMMR/MSI tumor is the pre-existing immunoreactive microenvironment. To promote and sustain immune activation, immunotherapy needs to be combined with targeted therapies to bypass defects in IFN- $\gamma$  signaling and antigen presentation machinery, and to inhibit upregulated oncogenic signaling pathways. Many related clinical trials in dMMR/MSI tumors are ongoing, as summarized in Table 5. Moreover, it is important to note that heterogeneity of the MMR system and microsatellite status may cover up the true potency to respond to immunotherapy. Large prospective studies are needed to identify the rate of ITH of dMMR/MSI with accurate detection methods.

#### Abbreviations

ACT: Adoptive cell transfer; CAR-T: Chimeric antigen receptor-T cells; cMS: Coding microsatellites; CNA: Copy-number alteration; ctDNA: Circulating tumor DNA; CTC: Circulating tumor cells; CTLA-4: Cytotoxic T lymphocyte-associated antigen-4; CXCL: Chemokine (C-X-C motif) ligand; dMMR: Deficient mismatch repair; FSP: Frameshift-derived peptides; HCC: Hepatocellular carcinoma; ICB: Immune checkpoint blockade; IDO: Indolamine-2,3-dioxygenase; IFN- $\gamma$ : Type II interferon; IFNGR 1/2: Interferon-gamma receptor 1/2; INCR1: IFN-stimulated noncoding RNA 1; IRE: IRF-1 response elements; IRF: Interferon regulatory factor 1; ITH: Intratumor heterogeneity; LAG-3: Lymphocyte activation gene-3; mCRC: Metastatic colorectal cancer; MHC: Major histocompatibility complex; MMR: Mismatch repair; MSI: Microsatellite instability; MSS: Microsatellite stable; MVD: Microvessel density; NAE: NEDD8-activating enzyme; NGS: Next-generation sequencing; NIR-II: The second near-infrared-window; NK: Nature killer; NSCLC: Non-small cell lung cancer; PD-1: Programmed cell death protein 1; PD-L1: Programmed cell death 1 ligand 1; pMMR: Proficient mismatch repair; scRNA-Seq: Single-cell RNA sequencing; SNV: Single-nucleotide variant; STAT: Signal transducers and activators of transcription; TCR: T cell receptor; TIL:

Tumor-infiltrating lymphocytes; TMB: Tumor mutation burden; WRN: Werner helicase;  $\beta$ 2M:  $\beta$ 2 Microglobulin.

#### Acknowledgements

Figures 1, 2 and 4 are created using BioRender.com. We are thankful to many scientists in the field whose seminal works are not cited due to space constraints. We would like to express our gratitude to all those who helped us during the writing of this review. We gratefully acknowledge the help of our supervisors, Professor Hong Shen, Professor Shan Zeng and Ms. Ying Han, who have offered us valuable suggestions in the academic studies. The completion of this review would not have been possible without their expert guidance and insightful criticism throughout the preparation of the review. We also owe a special debt of gratitude to Mr. Changjing Cai, Mr. Ziyang Feng, Mr. Hao Zhang and Mr. Chao Quan, from whose constructive suggestions we benefited a lot during the preparation of the manuscript. We are thankful to many colleagues and friends who give professional suggestions to this work. We would finally like to express our gratitude to our beloved parents for their unconditional love and support.

#### Authors' contributions

HS, SZ, WW and YL had the idea for the article, WW and YL performed the literature search and finished the manuscript and figures; WW and YL finished the tables; HS, SZ and YH made critical revisions and proofread the manuscript. All authors read and approved the final manuscript.

#### Funding

This study was supported by grants from the National Key R&D Program of China (No. 2018YFC1313300), National Natural Science Foundation of China (Nos. 81070362, 81172470, 81372629, 81772627, 81874073 and 81974384), two key projects from the Nature Science Foundation of Hunan Province (Nos. 2021JJ31092 & 2021JJ31048) and two projects from CSCO Cancer Research Foundation (Nos. Y-HR2019-0182 and Y-2019Genecast-043).

#### Availability of data and materials

Not applicable.

#### Declarations

#### Ethical approval and consent to participate

Not applicable.

#### Consent for publication

Not applicable.

#### Competing interests

The authors declare that they do not have any conflicts of interest related to this study. This manuscript has been read and approved by all the authors and has not been submitted to or is not under consideration for publication elsewhere.

#### Author details

<sup>1</sup>Department of Oncology, Xiangya Hospital, Central South University, Changsha, Hunan, People's Republic of China 410008. <sup>2</sup>Key Laboratory for Molecular Radiation Oncology of Hunan Province, Xiangya Hospital, Central South University, Changsha, Hunan, People's Republic of China 410008. <sup>3</sup>National Clinical Research Center for Geriatric Disorders, Xiangya Hospital, Central South University, Changsha, Hunan 410008, People's Republic of China.

Received: 15 August 2021 Accepted: 7 September 2021

Published online: 07 October 2021

#### References

- Gryfe R, Kim H, Hsieh ET, Aronson MD, Holowaty EJ, Bull SB, Redston M, Gallinger S. Tumor microsatellite instability and clinical outcome in young patients with colorectal cancer. *N Engl J Med*. 2000;342:69–77.
- Le DT, Durham JN, Smith KN, Wang H, Bartlett BR, Aulakh LK, Lu S, Kemberling H, Wilt C, Luber BS, et al. Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade. *Science*. 2017;357:409–13.

3. Berger MF, Hodis E, Heffernan TP, Deribe YL, Lawrence MS, Protopopov A, Ivanova E, Watson IR, Nickerson E, Ghosh P, et al. Melanoma genome sequencing reveals frequent PREX2 mutations. *Nature*. 2012;485:502–6.
4. Lee W, Jiang Z, Liu J, Haverty PM, Guan Y, Stinson J, Yue P, Zhang Y, Pant KP, Bhatt D, et al. The mutation spectrum revealed by paired genome sequences from a lung cancer patient. *Nature*. 2010;465:473–7.
5. Llosa NJ, Cruise M, Tam A, Wicks EC, Hechenbleikner EM, Taube JM, Blosser RL, Fan H, Wang H, Lubber BS, et al. The vigorous immune micro-environment of microsatellite instable colon cancer is balanced by multiple counter-inhibitory checkpoints. *Cancer Discov*. 2015;5:43–51.
6. Bai W, Ma J, Liu Y, Liang J, Wu Y, Yang X, Xu E, Li Y, Xi Y. Screening of MSI detection loci and their heterogeneity in East Asian colorectal cancer patients. *Cancer Med*. 2019;8:2157–66.
7. Grasso CS, Giannakis M, Wells DK, Hamada T, Mu XJ, Quist M, Nowak JA, Nishihara R, Qian ZR, Inamura K, et al. Genetic mechanisms of immune evasion in colorectal cancer. *Cancer Discov*. 2018;8:730–49.
8. Trabucco SE, Gowen K, Maund SL, Sanford E, Fabrizio DA, Hall MJ, Yakirevich E, Gregg JP, Stephens PJ, Frampton GM, et al. A novel next-generation sequencing approach to detecting microsatellite instability and pan-tumor characterization of 1000 microsatellite instability-high cases in 67,000 patient samples. *J Mol Diagn*. 2019;21:1053–66.
9. Sucker A, Zhao F, Pieper N, Heeke C, Maltaner R, Stadler N, Real B, Bielefeld N, Howe S, Weide B, et al. Acquired IFN $\gamma$  resistance impairs anti-tumor immunity and gives rise to T-cell-resistant melanoma lesions. *Nat Commun*. 2017;8:15440.
10. Sveen A, Johannessen B, Tengs T, Danielsen SA, Eilertsen IA, Lind GE, Berg KCG, Leite E, Meza-Zepeda LA, Domingo E, et al. Multilevel genomics of colorectal cancers with microsatellite instability-clinical impact of JAK1 mutations and consensus molecular subtype 1. *Genome Med*. 2017;9:46.
11. Maruvka YE, Mouw KW, Karlic R, Parasuraman P, Kamburov A, Polak P, Haradhvala NJ, Hess JM, Rheinbay E, Brody Y, et al. Analysis of somatic microsatellite indels identifies driver events in human tumors. *Nat Biotechnol*. 2017;35:951–9.
12. Marusyk A, Almendro V, Polyak K. Intra-tumour heterogeneity: a looking glass for cancer? *Nat Rev Cancer*. 2012;12:323–34.
13. Lee WC, Diao L, Wang J, Zhang J, Roarty EB, Varghese S, Chow CW, Fujimoto J, Behrens C, Cascone T, et al. Multiregion gene expression profiling reveals heterogeneity in molecular subtypes and immunotherapy response signatures in lung cancer. *Mod Pathol*. 2018;31:947–55.
14. Friemel J, Rechsteiner M, Frick L, Bohm F, Struckmann K, Egger M, Moch H, Heikenwalder M, Weber A. Intratumor heterogeneity in hepatocellular carcinoma. *Clin Cancer Res*. 2015;21:1951–61.
15. McGranahan N, Swanton C. Biological and therapeutic impact of intra-tumor heterogeneity in cancer evolution. *Cancer Cell*. 2015;27:15–26.
16. Hou Y, Guo H, Cao C, Li X, Hu B, Zhu P, Wu X, Wen L, Tang F, Huang Y, Peng J. Single-cell triple omics sequencing reveals genetic, epigenetic, and transcriptomic heterogeneity in hepatocellular carcinomas. *Cell Res*. 2016;26:304–19.
17. Jamal-Hanjani M, Wilson GA, McGranahan N, Birkbak NJ, Watkins TBK, Veeriah S, Shafi S, Johnson DH, Mitter R, Rosenthal R, et al. Tracking the evolution of non-small-cell lung cancer. *N Engl J Med*. 2017;376:2109–21.
18. Turajlic S, Xu H, Litchfield K, Rowan A, Horswell S, Chambers T, O'Brien T, Lopez JI, Watkins TBK, Nicol D, et al. Deterministic evolutionary trajectories influence primary tumor growth: TRACERx renal. *Cell*. 2018;173:595–610 e511.
19. Gao Q, Wang ZC, Duan M, Lin YH, Zhou XY, Worthley DL, Wang XY, Niu G, Xia Y, Deng M, et al. Cell culture system for analysis of genetic heterogeneity within hepatocellular carcinomas and response to pharmacologic agents. *Gastroenterology*. 2017;152:232–242 e234.
20. Lim B, Lin Y, Navin N. Advancing cancer research and medicine with single-cell genomics. *Cancer Cell*. 2020;37:456–70.
21. Hause RJ, Pritchard CC, Shendure J, Salipante SJ. Classification and characterization of microsatellite instability across 18 cancer types. *Nat Med*. 2016;22:1342–50.
22. Lee V, Murphy A, Le DT, Diaz LA Jr. Mismatch repair deficiency and response to immune checkpoint blockade. *Oncologist*. 2016;21:1200–11.
23. Saeed A, Park R, Al-Jumayli M, Al-Rajabi R, Sun W. Biologics, immunotherapy, and future directions in the treatment of advanced cholangiocarcinoma. *Clin Colorectal Cancer*. 2019;18:81–90.
24. Baretti M, Le DT. DNA mismatch repair in cancer. *Pharmacol Ther*. 2018;189:45–62.
25. Dudley JC, Lin MT, Le DT, Eshleman JR. Microsatellite Instability as a Biomarker for PD-1 Blockade. *Clin Cancer Res*. 2016;22:813–20.
26. Vilar E, Gruber SB. Microsatellite instability in colorectal cancer—the stable evidence. *Nat Rev Clin Oncol*. 2010;7:153–62.
27. Jiricny J. The multifaceted mismatch-repair system. *Nat Rev Mol Cell Biol*. 2006;7:335–46.
28. Evrard C, Tachon G, Randrian V, Karayan-Tapon L, Tougeron D. Microsatellite instability: diagnosis, heterogeneity, discordance, and clinical impact in colorectal cancer. *Cancers (Basel)*. 2019;11:1567.
29. Zhao P, Li L, Jiang X, Li Q. Mismatch repair deficiency/microsatellite instability-high as a predictor for anti-PD-1/PD-L1 immunotherapy efficacy. *J Hematol Oncol*. 2019;12:54.
30. Nicolaides NC, Papadopoulos N, Liu B, Wei YF, Carter KC, Ruben SM, Rosen CA, Haseltine WA, Fleischmann RD, Fraser CM, et al. Mutations of two PMS homologues in hereditary nonpolyposis colon cancer. *Nature*. 1994;371:75–80.
31. Salem ME, Bodor JN, Puccini A, Xiu J, Goldberg RM, Grothey A, Korn WM, Shields AF, Worrolow WM, Kim ES, et al. Relationship between MLH1, PMS2, MSH2 and MSH6 gene-specific alterations and tumor mutational burden in 1057 microsatellite instability-high solid tumors. *Int J Cancer*. 2020;147:2948–56.
32. Davies H, Bignell GR, Cox C, Stephens P, Edkins S, Clegg S, Teague J, Woffendin H, Garnett MJ, Bottomley W, et al. Mutations of the BRAF gene in human cancer. *Nature*. 2002;417:949–54.
33. French AJ, Sargent DJ, Burgart LJ, Foster NR, Kabat BF, Goldberg R, Shepherd L, Windschitl HE, Thibodeau SN. Prognostic significance of defective mismatch repair and BRAF V600E in patients with colon cancer. *Clin Cancer Res*. 2008;14:3408–15.
34. Hutchins G, Southward K, Handley K, Magill L, Beaumont C, Stahlschmidt J, Richman S, Chambers P, Seymour M, Kerr D, et al. Value of mismatch repair, KRAS, and BRAF mutations in predicting recurrence and benefits from chemotherapy in colorectal cancer. *J Clin Oncol*. 2011;29:1261–70.
35. Ribas A, Lawrence D, Atkinson V, Agarwal S, Miller WH Jr, Carlino MS, Fisher R, Long GV, Hodi FS, Tsoi J, et al. Combined BRAF and MEK inhibition with PD-1 blockade immunotherapy in BRAF-mutant melanoma. *Nat Med*. 2019;25:936–40.
36. van Wietmarschen N, Sridharan S, Nathan WJ, Tubbs A, Chan EM, Callen E, Wu W, Belinky F, Tripathi V, Wong N, et al. Repeat expansions confer WRN dependence in microsatellite-unstable cancers. *Nature*. 2020;586:292–8.
37. Brosh RM Jr. DNA helicases involved in DNA repair and their roles in cancer. *Nat Rev Cancer*. 2013;13:542–58.
38. Chan EM, Shibue T, McFarland JM, Gaeta B, Ghandi M, Dumont N, Gonzalez A, McPartlan JS, Li T, Zhang Y, et al. WRN helicase is a synthetic lethal target in microsatellite unstable cancers. *Nature*. 2019;568:551–6.
39. Lieb S, Blaha-Ostermann S, Kamper E, Rippka J, Schwarz C, Ehrenhofer-Wolfer K, Schlattl A, Wernitznig A, Lipp JJ, Nagasaka K, et al. Werner syndrome helicase is a selective vulnerability of microsatellite instability-high tumor cells. *Elife*. 2019;8:e43333.
40. Picco G, Cattaneo CM, van Vliet EJ, Crisafulli G, Rospo G, Consonni S, Vieira SF, Rodriguez IS, Cancelliere C, Banerjee R, et al. Werner helicase is a synthetic-lethal vulnerability in mismatch repair-deficient colorectal cancer refractory to targeted therapies, chemotherapy, and immunotherapy. *Cancer Discov*. 2021;11:1923–37.
41. Rosenthal R, Cadieux EL, Salgado R, Bakir MA, Moore DA, Hiley CT, Lund T, Tanic M, Reading JL, Joshi K, et al. Neoantigen-directed immune escape in lung cancer evolution. *Nature*. 2019;567:479–85.
42. Duan M, Hao J, Cui S, Worthley DL, Zhang S, Wang Z, Shi J, Liu L, Wang X, Ke A, et al. Diverse modes of clonal evolution in HBV-related hepatocellular carcinoma revealed by single-cell genome sequencing. *Cell Res*. 2018;28:359–73.
43. Luchini C, Bibeau F, Ligtenberg MJL, Singh N, Nottegar A, Bosse T, Miller R, Riaz N, Douillard JY, Andre F, Scarpa A. ESMO recommendations on microsatellite instability testing for immunotherapy in cancer, and its relationship with PD-1/PD-L1 expression and tumour

- mutational burden: a systematic review-based approach. *Ann Oncol*. 2019;30:1232–43.
44. Touat M, Li YY, Boynton AN, Spurr LF, Iorgulescu JB, Bohrsen CL, Cortes-Ciriano I, Birzu C, Geduldig JE, Pelton K, et al. Mechanisms and therapeutic implications of hypermutation in gliomas. *Nature*. 2020;580:517–23.
  45. Rooney MS, Shukla SA, Wu CJ, Getz G, Hacohen N. Molecular and genetic properties of tumors associated with local immune cytolytic activity. *Cell*. 2015;160:48–61.
  46. Wolf Y, Bartok O, Patkar S, Eli GB, Cohen S, Litchfield K, Levy R, Jimenez-Sanchez A, Trabish S, Lee JS, et al. UVB-Induced tumor heterogeneity diminishes immune response in melanoma. *Cell*. 2019;179:219–235 e221.
  47. Gerlinger M, Rowan AJ, Horswell S, Math M, Larkin J, Endesfelder D, Gronroos E, Martinez P, Matthews N, Stewart A, et al. Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. *N Engl J Med*. 2012;366:883–92.
  48. Lee-Six H, Olafsson S, Ellis P, Osborne RJ, Sanders MA, Moore L, Georgakopoulos N, Torrente F, Noorani A, Goddard M, et al. The landscape of somatic mutation in normal colorectal epithelial cells. *Nature*. 2019;574:532–7.
  49. Anagnostou V, Smith KN, Forde PM, Niknafs N, Bhattacharya R, White J, Zhang T, Adleff V, Phallen J, Wali N, et al. Evolution of neoantigen landscape during immune checkpoint blockade in non-small cell lung cancer. *Cancer Discov*. 2017;7:264–76.
  50. Baker AM, Cross W, Curtius K, Al Bakir I, Choi CR, Davis HL, Temko D, Biswas S, Martinez P, Williams MJ, et al. Evolutionary history of human colitis-associated colorectal cancer. *Gut*. 2019;68:985–95.
  51. Field MG, Durante MA, Anbunathan H, Cai LZ, Decatur CL, Bowcock AM, Kurtenbach S, Harbour JW. Punctuated evolution of canonical genomic aberrations in uveal melanoma. *Nat Commun*. 2018;9:116.
  52. Bian S, Hou Y, Zhou X, Li X, Yong J, Wang Y, Wang W, Yan J, Hu B, Guo H, et al. Single-cell multiomics sequencing and analyses of human colorectal cancer. *Science*. 2018;362:1060–3.
  53. Xu LX, He MH, Dai ZH, Yu J, Wang JG, Li XC, Jiang BB, Ke ZF, Su TH, Peng ZW, et al. Genomic and transcriptional heterogeneity of multifocal hepatocellular carcinoma. *Ann Oncol*. 2019;30:990–7.
  54. Ran X, Xiao J, Zhang Y, Teng H, Cheng F, Chen H, Zhang K, Sun Z. Low intratumor heterogeneity correlates with increased response to PD-1 blockade in renal cell carcinoma. *Ther Adv Med Oncol*. 2020;12:1758835920977117.
  55. Nguyen PHD, Ma S, Phua CZJ, Kaya NA, Lai HLH, Lim CJ, Lim JQ, Wasser M, Lai L, Tam WL, et al. Intratumoural immune heterogeneity as a hallmark of tumour evolution and progression in hepatocellular carcinoma. *Nat Commun*. 2021;12:227.
  56. Taube JM, Anders RA, Young GD, Xu H, Sharma R, McMiller TL, Chen S, Klein AP, Pardoll DM, Topalian SL, Chen L. Colocalization of inflammatory response with B7–h1 expression in human melanocytic lesions supports an adaptive resistance mechanism of immune escape. *Sci Transl Med*. 2012;4:127ra137.
  57. Topalian SL, Hodi FS, Brahmer JR, Gettinger SN, Smith DC, McDermott DF, Powderly JD, Carvajal RD, Sosman JA, Atkins MB, et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. *N Engl J Med*. 2012;366:2443–54.
  58. Ma K-Y, Schonnesen AA, Brock A, Van Den Berg C, Eckhardt SG, Liu Z, Jiang N. Single-cell RNA sequencing of lung adenocarcinoma reveals heterogeneity of immune response-related genes. *JCI Insight*. 2019;4:e121387.
  59. Le DT, Uram JN, Wang H, Bartlett BR, Kemberling H, Eyring AD, Skora AD, Luber BS, Azad NS, Laheru D, et al. PD-1 Blockade in tumors with mismatch-repair deficiency. *N Engl J Med*. 2015;372:2509–20.
  60. Jhunjhunwala S, Hammer C, Delamarre L. Antigen presentation in cancer: insights into tumour immunogenicity and immune evasion. *Nat Rev Cancer*. 2021;21:298–312.
  61. Sharonov GV, Serebrovskaya EO, Yuzhakova DV, Britanova OV, Chudakov DM. B cells, plasma cells and antibody repertoires in the tumour micro-environment. *Nat Rev Immunol*. 2020;20:294–307.
  62. Riaz N, Havel JJ, Makarov V, Desrichard A, Urba WJ, Sims JS, Hodi FS, Martin-Algarra S, Mandal R, Sharfman WH, et al. Tumor and microenvironment evolution during immunotherapy with nivolumab. *Cell*. 2017;171:934–949 e916.
  63. Samstein RM, Lee CH, Shoushtari AN, Hellmann MD, Shen R, Janjigian YY, Barron DA, Zehir A, Jordan EJ, Omuro A, et al. Tumor mutational load predicts survival after immunotherapy across multiple cancer types. *Nat Genet*. 2019;51:202–6.
  64. Rizvi H, Sanchez-Vega F, La K, Chatila W, Jonsson P, Halpenny D, Plodkowski A, Long N, Sauter JL, Rekhtman N, et al. Molecular determinants of response to anti-programmed cell death (PD)-1 and anti-programmed death-ligand 1 (PD-L1) blockade in patients with non-small-cell lung cancer profiled with targeted next-generation sequencing. *J Clin Oncol*. 2018;36:633–41.
  65. Reuben A, Gittelman R, Gao J, Zhang J, Yusko EC, Wu CJ, Emerson R, Zhang J, Tipton C, Li J, et al. TCR Repertoire Intratumor Heterogeneity in localized lung adenocarcinomas: an association with predicted neoantigen heterogeneity and postsurgical recurrence. *Cancer Discov*. 2017;7:1088–97.
  66. Joshi K, de Massy MR, Ismail M, Reading JL, Uddin I, Woolston A, Hatipoglu E, Oakes T, Rosenthal R, Peacock T, et al. Spatial heterogeneity of the T cell receptor repertoire reflects the mutational landscape in lung cancer. *Nat Med*. 2019;25:1549–59.
  67. Kuang M, Cheng J, Zhang C, Feng L, Xu X, Zhang Y, Zu M, Cui J, Yu H, Zhang K, et al. A novel signature for stratifying the molecular heterogeneity of the tissue-infiltrating T-cell receptor repertoire reflects gastric cancer prognosis. *Sci Rep*. 2017;7:7762.
  68. Liaskou E, Klemsdal Henriksen EK, Holm K, Kaveh F, Hamm D, Fear J, Viken MK, Hov JR, Melum E, Robins H, et al. High-throughput T-cell receptor sequencing across chronic liver diseases reveals distinct disease-associated repertoires. *Hepatology*. 2016;63:1608–19.
  69. Lin KR, Deng FW, Jin YB, Chen XP, Pan YM, Cui JH, You ZX, Chen HW, Luo W. T cell receptor repertoire profiling predicts the prognosis of HBV-associated hepatocellular carcinoma. *Cancer Med*. 2018;7:3755–62.
  70. Tran E, Robbins PF, Rosenberg SA. “Final common pathway” of human cancer immunotherapy: targeting random somatic mutations. *Nat Immunol*. 2017;18:255–62.
  71. Zhang C, Ding H, Huang H, Palashati H, Miao Y, Xiong H, Lu Z. TCR repertoire intratumor heterogeneity of CD4(+) and CD8(+) T cells in centers and margins of localized lung adenocarcinomas. *Int J Cancer*. 2019;144:818–27.
  72. Zhang Q, Lou Y, Yang J, Wang J, Feng J, Zhao Y, Wang L, Huang X, Fu Q, Ye M, et al. Integrated multiomic analysis reveals comprehensive tumour heterogeneity and novel immunophenotypic classification in hepatocellular carcinomas. *Gut*. 2019;68:2019–31.
  73. Liu YY, Yang QF, Yang JS, Cao RB, Liang JY, Liu YT, Zeng YL, Chen S, Xia XF, Zhang K, Liu L. Characteristics and prognostic significance of profiling the peripheral blood T-cell receptor repertoire in patients with advanced lung cancer. *Int J Cancer*. 2019;145:1423–31.
  74. Zhang Y, Zhu Y, Wang J, Xu Y, Wang Z, Liu Y, Di X, Feng L, Zhang Y. A comprehensive model based on temporal dynamics of peripheral T cell repertoire for predicting post-treatment distant metastasis of nasopharyngeal carcinoma. *Cancer Immunol Immunother*. 2021. <https://doi.org/10.1007/s00262-021-03016-0>.
  75. Guo L, Bi X, Li Y, Wen L, Zhang W, Jiang W, Ma J, Feng L, Zhang K, Shou J. Characteristics, dynamic changes, and prognostic significance of TCR repertoire profiling in patients with renal cell carcinoma. *J Pathol*. 2020;251:26–37.
  76. Hectors SJ, Wagner M, Bane O, Besa C, Lewis S, Remark R, Chen N, Fiel MI, Zhu H, Gnjjatic S, et al. Quantification of hepatocellular carcinoma heterogeneity with multiparametric magnetic resonance imaging. *Sci Rep*. 2017;7:2452.
  77. Kurebayashi Y, Ojima H, Tsujikawa H, Kubota N, Maehara J, Abe Y, Kitago M, Shinoda M, Kitagawa Y, Sakamoto M. Landscape of immune micro-environment in hepatocellular carcinoma and its additional impact on histological and molecular classification. *Hepatology*. 2018;68:1025–41.
  78. Chew V, Chen J, Lee D, Loh E, Lee J, Lim KH, Weber A, Slinkamenac K, Poon RT, Yang H, et al. Chemokine-driven lymphocyte infiltration: an early intratumoural event determining long-term survival in resectable hepatocellular carcinoma. *Gut*. 2012;61:427–38.
  79. Okabe M, Toh U, Iwakuma N, Saku S, Akashi M, Kimitsuki Y, Seki N, Kawahara A, Ogo E, Itoh K, Akagi Y. Predictive factors of the tumor immunological microenvironment for long-term follow-up in early stage breast cancer. *Cancer Sci*. 2017;108:81–90.

80. O'Donnell JS, Teng MWL, Smyth MJ. Cancer immunoeediting and resistance to T cell-based immunotherapy. *Nat Rev Clin Oncol*. 2019;16:151–67.
81. Overman MJ, McDermott R, Leach JL, Lonardi S, Lenz H-J, Morse MA, Desai J, Hill A, Axelson M, Moss RA, et al. Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer (CheckMate 142): an open-label, multicentre, phase 2 study. *Lancet Oncol*. 2017;18:1182–91.
82. Petrelli F, Ghidini M, Ghidini A, Tomasello G. Outcomes following immune checkpoint inhibitor treatment of patients with microsatellite instability-high cancers: a systematic review and meta-analysis. *JAMA Oncol*. 2020;6:1068–71.
83. Overman MJ, Lonardi S, Wong KYM, Lenz HJ, Gelsomino F, Aglietta M, Morse MA, Van Cutsem E, McDermott R, Hill A, et al. Durable clinical benefit with nivolumab plus ipilimumab in DNA mismatch repair-deficient/microsatellite instability-high metastatic colorectal cancer. *J Clin Oncol*. 2018;36:773–9.
84. Feng L, Qian H, Yu X, Liu K, Xiao T, Zhang C, Kuang M, Cheng S, Li X, Wan J, Zhang K. Heterogeneity of tumor-infiltrating lymphocytes ascribed to local immune status rather than neoantigens by multi-omics analysis of glioblastoma multiforme. *Sci Rep*. 2017;7:6968.
85. Ribas A, Wolchok JD. Cancer immunotherapy using checkpoint blockade. *Science*. 2018;359:1350–5.
86. Minn AJ, Wherry EJ. Combination cancer therapies with immune checkpoint blockade: convergence on interferon signaling. *Cell*. 2016;165:272–5.
87. Sharma P, Hu-Lieskovan S, Wargo JA, Ribas A. Primary, adaptive, and acquired resistance to cancer immunotherapy. *Cell*. 2017;168:707–23.
88. Refaeli Y, Van Parijs L, Alexander SI, Abbas AK. Interferon gamma is required for activation-induced death of T lymphocytes. *J Exp Med*. 2002;196:999–1005.
89. Mo X, Zhang H, Preston S, Martin K, Zhou B, Vadalina N, Gamero AM, Soboloff J, Tempera I, Zaidi MR. Interferon-gamma signaling in melanocytes and melanoma cells regulates expression of CTLA-4. *Cancer Res*. 2018;78:436–50.
90. Zhu J, Powis de Tenbossche CG, Cane S, Colau D, van Baren N, Lurquin C, Schmitt-Verhulst AM, Liljestrom P, Uyttenhove C, Van den Eynde BJ. Resistance to cancer immunotherapy mediated by apoptosis of tumor-infiltrating lymphocytes. *Nat Commun*. 2017;8:1404.
91. Horton BL, Williams JB, Cabanov A, Spranger S, Gajewski TF. Intratumoral CD8(+) T-cell apoptosis is a major component of T-cell dysfunction and impedes antitumor immunity. *Cancer Immunol Res*. 2018;6:14–24.
92. De Smedt L, Lemahieu J, Palmans S, Govaere O, Tousseyn T, Van Cutsem E, Prenen H, Tejpar S, Spaepen M, Matthijs G, et al. Microsatellite unstable vs stable colon carcinomas: analysis of tumour heterogeneity, inflammation and angiogenesis. *Br J Cancer*. 2015;113:500–9.
93. Galon J, Costes A, Sanchez-Cabo F, Kirilovsky A, Mlecnik B, Lagorce-Pages C, Tosolini M, Camus M, Berger A, Wind P, et al. Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. *Science*. 2006;313:1960–4.
94. Burugu S, Gao D, Leung S, Chia SK, Nielsen TO. LAG-3+ tumor infiltrating lymphocytes in breast cancer: clinical correlates and association with PD-1/PD-L1+ tumors. *Ann Oncol*. 2017;28:2977–84.
95. Schrock AB, Ouyang C, Sandhu J, Sokol E, Jin D, Ross JS, Miller VA, Lim D, Amanam I, Chao J, et al. Tumor mutational burden is predictive of response to immune checkpoint inhibitors in MSI-high metastatic colorectal cancer. *Ann Oncol*. 2019;30:1096–103.
96. Rizvi NA, Hellmann MD, Snyder A, Kvistborg P, Makarov V, Havel JJ, Lee W, Yuan J, Wong P, Ho TS, et al. Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer. *Science*. 2015;348:124–8.
97. Snyder A, Makarov V, Merghoub T, Yuan J, Zaretsky JM, Desrichard A, Walsh LA, Postow MA, Wong P, Ho TS, et al. Genetic basis for clinical response to CTLA-4 blockade in melanoma. *N Engl J Med*. 2014;371:2189–99.
98. Tosolini M, Kirilovsky A, Mlecnik B, Fredriksen T, Mauger S, Bindea G, Berger A, Bruneval P, Fridman W-H, Pagès F, Galon J. Clinical impact of different classes of infiltrating T cytotoxic and helper cells (Th1, Th2, Treg, Th17) in patients with colorectal cancer. *Can Res*. 2011;71:1263–71.
99. Dolcetti R, Viel A, Doglioni C, Russo A, Guidoboni M, Capozzi E, Vecchiato N, Macri E, Fornasarig M, Boiocchi M. High prevalence of activated intraepithelial cytotoxic T lymphocytes and increased neoplastic cell apoptosis in colorectal carcinomas with microsatellite instability. *Am J Pathol*. 1999;154:1805–13.
100. Azimi F, Scolyer RA, Rumcheva P, Moncrieff M, Murali R, McCarthy SW, Saw RP, Thompson JF. Tumor-infiltrating lymphocyte grade is an independent predictor of sentinel lymph node status and survival in patients with cutaneous melanoma. *J Clin Oncol*. 2012;30:2678–83.
101. Ogino S, Noshro K, Irahara N, Meyerhardt JA, Baba Y, Shima K, Glickman JN, Ferrone CR, Mino-Kenudson M, Tanaka N, et al. Lymphocytic reaction to colorectal cancer is associated with longer survival, independent of lymph node count, microsatellite instability, and CpG island methylator phenotype. *Clin Cancer Res*. 2009;15:6412–20.
102. Thomas NE, Busam KJ, From L, Kricaker A, Armstrong BK, Anton-Culver H, Gruber SB, Gallagher RP, Zanetti R, Rosso S, et al. Tumor-infiltrating lymphocyte grade in primary melanomas is independently associated with melanoma-specific survival in the population-based genes, environment and melanoma study. *J Clin Oncol*. 2013;31:4252–9.
103. Chen PL, Roh W, Reuben A, Cooper ZA, Spencer CN, Prieto PA, Miller JP, Bassett RL, Gopalakrishnan V, Wani K, et al. Analysis of immune signatures in longitudinal tumor samples yields insight into biomarkers of response and mechanisms of resistance to immune checkpoint blockade. *Cancer Discov*. 2016;6:827–37.
104. Senbabaoglu Y, Gejman RS, Winer AG, Liu M, Van Allen EM, de Velasco G, Miao D, Ostrovskaya I, Drill E, Luna A, et al. Tumor immune microenvironment characterization in clear cell renal cell carcinoma identifies prognostic and immunotherapeutically relevant messenger RNA signatures. *Genome Biol*. 2016;17:231.
105. Cui C, Tian X, Wu J, Zhang C, Tan Q, Guan X, Dong B, Zhao M, Lu Z, Hao C. T cell receptor beta-chain repertoire analysis of tumor-infiltrating lymphocytes in pancreatic cancer. *Cancer Sci*. 2019;110:61–71.
106. Jeantet M, Tougeron D, Tachon G, Cortes U, Archambault C, Fromont G, Karayan-Tapon L. High intra- and inter-tumoral heterogeneity of RAS mutations in colorectal cancer. *Int J Mol Sci*. 2015;2016:17.
107. Nusinow DP, Szpyt J, Ghandi M, Rose CM, McDonald ER 3rd, Kalocsay M, Jane-Valbuena J, Gelfand E, Schweppe DK, Jedrychowski M, et al. Quantitative proteomics of the cancer cell line encyclopedia. *Cell*. 2020;180:387–402 e316.
108. Carethers JM, Jung BH. Genetics and genetic biomarkers in sporadic colorectal cancer. *Gastroenterology*. 2015;149:1177–1190 e1173.
109. Vadakekolathu J, Lai C, Reeder S, Church SE, Hood T, Lourdasamy A, Rettig MP, Aldoss I, Advani AS, Godwin J, et al. TP53 abnormalities correlate with immune infiltration and associate with response to flutemetuzumab immunotherapy in AML. *Blood Adv*. 2020;4:5011–24.
110. Dong ZY, Zhong WZ, Zhang XC, Su J, Xie Z, Liu SY, Tu HY, Chen HJ, Sun YL, Zhou Q, et al. Potential predictive value of TP53 and KRAS mutation status for response to PD-1 blockade immunotherapy in lung adenocarcinoma. *Clin Cancer Res*. 2017;23:3012–24.
111. Droeser RA, Hirt C, Viehl CT, Frey DM, Nebiker C, Huber X, Zlobec I, Eppenberger-Castori S, Tzankov A, Rosso R, et al. Clinical impact of programmed cell death ligand 1 expression in colorectal cancer. *Eur J Cancer*. 2013;49:2233–42.
112. Taube JM, Klein A, Brahmer JR, Xu H, Pan X, Kim JH, Chen L, Pardoll DM, Topalian SL, Anders RA. Association of PD-1, PD-1 ligands, and other features of the tumor immune microenvironment with response to anti-PD-1 therapy. *Clin Cancer Res*. 2014;20:5064–74.
113. Rosenberg JE, Hoffman-Censits J, Powles T, van der Heijden MS, Balar AV, Necchi A, Dawson N, O'Donnell PH, Balmanoukian A, Loriot Y, et al. Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial. *The Lancet*. 2016;387:1909–20.
114. Bouffert E, Larouche V, Campbell BB, Merico D, de Borja R, Aronson M, Durno C, Krueger J, Cabric V, Ramaswamy V, et al. Immune checkpoint inhibition for hypermutant glioblastoma multiforme resulting from germline biallelic mismatch repair deficiency. *J Clin Oncol*. 2016;34:2206–11.
115. Castro MP, Goldstein N. Mismatch repair deficiency associated with complete remission to combination programmed cell death ligand immune therapy in a patient with sporadic urothelial carcinoma: immunotherapeutic considerations. *J Immunother Cancer*. 2015;3:58.

116. Kelly RJ, Lee J, Bang YJ, Almhanna K, Blum-Murphy M, Catenacci DVT, Chung HC, Wainberg ZA, Gibson MK, Lee KW, et al. Safety and efficacy of durvalumab and tremelimumab alone or in combination in patients with advanced gastric and gastroesophageal junction adenocarcinoma. *Clin Cancer Res*. 2020;26:846–54.
117. Day EK, Carmichael AJ, ten Berge IJ, Waller EC, Sissons JG, Wills MR. Rapid CD8+ T cell repertoire focusing and selection of high-affinity clones into memory following primary infection with a persistent human virus: human cytomegalovirus. *J Immunol*. 2007;179:3203–13.
118. McGranahan N, Swanton C. Clonal heterogeneity and tumor evolution: past, present, and the future. *Cell*. 2017;168:613–28.
119. Chen Z, Zhang C, Pan Y, Xu R, Xu C, Chen Z, Lu Z, Ke Y. T cell receptor beta-chain repertoire analysis reveals intratumour heterogeneity of tumour-infiltrating lymphocytes in oesophageal squamous cell carcinoma. *J Pathol*. 2016;239:450–8.
120. Jia Q, Chiu L, Wu S, Bai J, Peng L, Zheng L, Zang R, Li X, Yuan B, Gao Y, et al. Tracking neoantigens by personalized circulating tumor DNA sequencing during checkpoint blockade immunotherapy in non-small cell lung cancer. *Adv Sci (Weinh)*. 2020;7:1903410.
121. Liu Z, Li JP, Chen M, Wu M, Shi Y, Li W, Teijaro JR, Wu P. Detecting tumor antigen-specific T cells via interaction-dependent fucosyl-biotinylation. *Cell*. 2020;183:1117–1133. 119.
122. Unitt E, Rushbrook SM, Marshall A, Davies S, Gibbs P, Morris LS, Coleman N, Alexander GJ. Compromised lymphocytes infiltrate hepatocellular carcinoma: the role of T-regulatory cells. *Hepatology*. 2005;41:722–30.
123. Ahmadzadeh M, Pasetto A, Jia L, Deniger DC, Stevanovic S, Robbins PF, Rosenberg SA. Tumor-infiltrating human CD4(+) regulatory T cells display a distinct TCR repertoire and exhibit tumor and neoantigen reactivity. *Sci Immunol*. 2019;4:eaa04310.
124. Zhang Y, Zhu W, Zhang X, Qu Q, Zhang L. Expression and clinical significance of programmed death-1 on lymphocytes and programmed death ligand-1 on monocytes in the peripheral blood of patients with cervical cancer. *Oncol Lett*. 2017;14:7225–31.
125. Cui JH, Lin KR, Yuan SH, Jin YB, Chen XP, Su XK, Jiang J, Pan YM, Mao SL, Mao XF, Luo W. TCR repertoire as a novel indicator for immune monitoring and prognosis assessment of patients with cervical cancer. *Front Immunol*. 2018;9:2729.
126. Gros A, Robbins PF, Yao X, Li YF, Turcotte S, Tran E, Wunderlich JR, Mixon A, Farid S, Dudley ME, et al. PD-1 identifies the patient-specific CD8(+) tumor-reactive repertoire infiltrating human tumors. *J Clin Invest*. 2014;124:2246–59.
127. Thommen DS, Koelzer VH, Herzig P, Roller A, Trefny M, Dimeloe S, Kiialainen A, Hanhart J, Schill C, Hess C, et al. A transcriptionally and functionally distinct PD-1(+) CD8(+) T cell pool with predictive potential in non-small-cell lung cancer treated with PD-1 blockade. *Nat Med*. 2018;24:994–1004.
128. Zerdes I, Matikas A, Bergh J, Rassidakis GZ, Foukakis T. Genetic, transcriptional and post-translational regulation of the programmed death protein ligand 1 in cancer: biology and clinical correlations. *Oncogene*. 2018;37:4639–61.
129. Shevtsov M, Sato H, Multhoff G, Shibata A. Novel approaches to improve the efficacy of immuno-radiotherapy. *Front Oncol*. 2019;9:156.
130. Mineo M, Lyons SM, Zdioruk M, von Spreckelsen N, Ferrer-Luna R, Ito H, Alayo QA, Kharel P, Giantini Larsen A, Fan WY, et al. Tumor interferon signaling is regulated by a lncRNA INCR1 transcribed from the PD-L1 Locus. *Mol Cell*. 2020;78:1207–1223 e1208.
131. Yan Y, Zheng L, Du Q, Yan B, Geller DA. Interferon regulatory factor 1 (IRF-1) and IRF-2 regulate PD-L1 expression in hepatocellular carcinoma (HCC) cells. *Cancer Immunol Immunother*. 2020;69:1891–903.
132. Zheng H, Pomyen Y, Hernandez MO, Li C, Livak F, Tang W, Dang H, Greten TF, Davis JL, Zhao Y, et al. Single-cell analysis reveals cancer stem cell heterogeneity in hepatocellular carcinoma. *Hepatology*. 2018;68:127–40.
133. Fu Y, Liu S, Zeng S, Shen H. From bench to bed: the tumor immune microenvironment and current immunotherapeutic strategies for hepatocellular carcinoma. *J Exp Clin Cancer Res*. 2019;38:396.
134. Sharma P, Retz M, Siefker-Radtke A, Baron A, Necchi A, Bedke J, Plimack ER, Vaena D, Grimm M-O, Bracarda S, et al. Nivolumab in metastatic urothelial carcinoma after platinum therapy (CheckMate 275): a multi-centre, single-arm, phase 2 trial. *Lancet Oncol*. 2017;18:312–22.
135. Hamid O, Schmidt H, Nissán A, Ridolfi L, Aamdal S, Hansson J, Guida M, Hyams DM, Gomez H, Bastholt L, et al. A prospective phase II trial exploring the association between tumor microenvironment biomarkers and clinical activity of ipilimumab in advanced melanoma. *J Transl Med*. 2011;9:204.
136. Johnson DB, Estrada MV, Salgado R, Sanchez V, Doxie DB, Opaalenik SR, Vilgelm AE, Feld E, Johnson AS, Greenplate AR, et al. Melanoma-specific MHC-II expression represents a tumour-autonomous phenotype and predicts response to anti-PD-1/PD-L1 therapy. *Nat Commun*. 2016;7:10582.
137. Higgs BW, Morehouse CA, Streicher K, Brohawn PZ, Pilataxi F, Gupta A, Ranade K. Interferon gamma messenger RNA signature in tumor biopsies predicts outcomes in patients with non-small cell lung carcinoma or urothelial cancer treated with durvalumab. *Clin Cancer Res*. 2018;24:3857–66.
138. Zhai W, Zhou X, Wang H, Li W, Chen G, Sui X, Li G, Qi Y, Gao Y. A novel cyclic peptide targeting LAG-3 for cancer immunotherapy by activating antigen-specific CD8(+) T cell responses. *Acta Pharm Sin B*. 2020;10:1047–60.
139. Lichtenegger FS, Rothe M, Schnorfeil FM, Deiser K, Krupka C, Augsberger C, Schluter M, Neitz J, Subklewe M. Targeting LAG-3 and PD-1 to enhance T cell activation by antigen-presenting cells. *Front Immunol*. 2018;9:385.
140. Huang RY, Francois A, McGray AR, Miliotto A, Odunsi K. Compensatory upregulation of PD-1, LAG-3, and CTLA-4 limits the efficacy of single-agent checkpoint blockade in metastatic ovarian cancer. *Oncimmunology*. 2017;6:e1249561.
141. Harris-Bookman S, Mathios D, Martin AM, Xia Y, Kim E, Xu H, Belcaid Z, Polanczyk M, Barberi T, Theodoros D, et al. Expression of LAG-3 and efficacy of combination treatment with anti-LAG-3 and anti-PD-1 monoclonal antibodies in glioblastoma. *Int J Cancer*. 2018;143:3201–8.
142. Matsuzaki J, Gnjatich S, Mhawech-Fauceglia P, Beck A, Miller A, Tsuji T, Eppolito C, Qian F, Lele S, Shrikant P, et al. Tumor-infiltrating NY-ESO-1-specific CD8+ T cells are negatively regulated by LAG-3 and PD-1 in human ovarian cancer. *Proc Natl Acad Sci USA*. 2010;107:7875–80.
143. Grosso JF, Goldberg MV, Getnet D, Bruno TC, Yen HR, Pyle KJ, Hipkiss E, Vignali DA, Pardoll DM, Drake CG. Functionally distinct LAG-3 and PD-1 subsets on activated and chronically stimulated CD8 T cells. *J Immunol*. 2009;182:6659–69.
144. Yu X, Huang X, Chen X, Liu J, Wu C, Pu Q, Wang Y, Kang X, Zhou L. Characterization of a novel anti-human lymphocyte activation gene 3 (LAG-3) antibody for cancer immunotherapy. *MAbs*. 2019;11:1139–48.
145. Linette GP, Becker-Hapak M, Skidmore ZL, Baroja ML, Xu C, Hundal J, Spencer DH, Fu W, Cummins C, Robnett M, et al. Immunological ignorance is an enabling feature of the oligo-clonal T cell response to melanoma neoantigens. *Proc Natl Acad Sci USA*. 2019;116:23662–70.
146. Zacharakis N, Chinnasamy H, Black M, Xu H, Lu YC, Zheng Z, Pasetto A, Langhan M, Shelton T, Prickett T, et al. Immune recognition of somatic mutations leading to complete durable regression in metastatic breast cancer. *Nat Med*. 2018;24:724–30.
147. Peng W, Liu C, Xu C, Lou Y, Chen J, Yang Y, Yagita H, Overwijk WW, Lizee G, Radvanyi L, Hwu P. PD-1 blockade enhances T-cell migration to tumors by elevating IFN-gamma inducible chemokines. *Cancer Res*. 2012;72:5209–18.
148. Chen H, Liakou CI, Kamat A, Pettaway C, Ward JF, Tang DN, Sun J, Jungbluth AA, Troncso P, Logothetis C, Sharma P. Anti-CTLA-4 therapy results in higher CD4+ICOShi T cell frequency and IFN-gamma levels in both nonmalignant and malignant prostate tissues. *Proc Natl Acad Sci USA*. 2009;106:27279–34.
149. John LB, Devaud C, Duong CP, Yong CS, Beavis PA, Haynes NM, Chow MT, Smyth MJ, Kershaw MH, Darcy PK. Anti-PD-1 antibody therapy potently enhances the eradication of established tumors by gene-modified T cells. *Clin Cancer Res*. 2013;19:5636–46.
150. Efferm M, Glodde N, Braun M, Liebing J, Boll HN, Yong M, Bawden E, Hinze D, van den Boorn-Konijnenberg D, Daoud M, et al. Adoptive T cell therapy targeting different gene products reveals diverse and context-dependent immune evasion in melanoma. *Immunity*. 2020;53:564–580 e569.
151. von Knebel DM, Kloor M. Towards a vaccine to prevent cancer in Lynch syndrome patients. *Fam Cancer*. 2013;12:307–12.



152. Kloor M, von Knebel DM. The immune biology of microsatellite-unstable cancer. *Trends Cancer*. 2016;2:121–33.
153. Kloor M, Reuschenbach M, Pauligk C, Karbach J, Rafiyan MR, Al-Batran SE, Tariverdian M, Jager E, von Knebel DM. A frameshift peptide neoantigen-based vaccine for mismatch repair-deficient cancers: a phase I/IIa clinical trial. *Clin Cancer Res*. 2020;26:4503–10.
154. Leoni G, D'Alise AM, Cotugno G, Langone F, Garzia I, De Lucia M, Fichera I, Vitale R, Bignone V, Tucci FG, et al. A genetic vaccine encoding shared cancer neoantigens to treat tumors with microsatellite instability. *Cancer Res*. 2020;80:3972–82.
155. Woerner SM, Kloor M, von Knebel DM, Gebert JF. Microsatellite instability in the development of DNA mismatch repair deficient tumors. *Cancer Biomark*. 2006;2:69–86.
156. Woerner SM, Kloor M, Mueller A, Rueschoff J, Friedrichs N, Buettner R, Buzello M, Kienle P, Knaebel HP, Kunstmann E, et al. Microsatellite instability of selective target genes in HNPCC-associated colon adenomas. *Oncogene*. 2005;24:2525–35.
157. Kjeldsen JW, Iversen TZ, Engell-Noerregaard L, Mellemgaard A, Andersen MH, Svane IM. Durable clinical responses and long-term follow-up of stage II–IV non-small-cell lung cancer (NSCLC) patients treated with IDO peptide vaccine in a phase I study—A brief research report. *Front Immunol*. 2018;9:2145.
158. Gao S, Yang X, Xu J, Qiu N, Zhai G. Nanotechnology for boosting cancer immunotherapy and remodeling tumor microenvironment: the horizons in cancer treatment. *ACS Nano*. 2021.
159. Meng X, Wang J, Zhou J, Tian Q, Qie B, Zhou G, Duan W, Zhu Y. Tumor cell membrane-based peptide delivery system targeting the tumor microenvironment for cancer immunotherapy and diagnosis. *Acta Biomater*. 2021;127:266–75.
160. Tan X, Huang J, Wang Y, He S, Jia L, Zhu Y, Pu K, Zhang Y, Yang X. Transformable nanosensitizer with tumor microenvironment-activated sonodynamic process and calcium release for enhanced cancer immunotherapy. *Angew Chem Int Ed Engl*. 2021;60:14051–9.
161. Yang M, Li J, Gu P, Fan X. The application of nanoparticles in cancer immunotherapy: targeting tumor microenvironment. *Bioact Mater*. 2021;6:1973–87.
162. Zhao H, Zhao B, Wu L, Xiao H, Ding K, Zheng C, Song Q, Sun L, Wang L, Zhang Z. Amplified cancer immunotherapy of a surface-engineered antigenic microparticle vaccine by synergistically modulating tumor microenvironment. *ACS Nano*. 2019;13:12553–66.
163. Tang H, Xu X, Chen Y, Xin H, Wan T, Li B, Pan H, Li D, Ping Y. Reprogramming the tumor microenvironment through second-near-infrared-window photothermal genome editing of PD-L1 Mediated by supramolecular gold nanorods for enhanced cancer immunotherapy. *Adv Mater*. 2021;33:e2006003.
164. Gong C, Yu X, Zhang W, Han L, Wang R, Wang Y, Gao S, Yuan Y. Regulating the immunosuppressive tumor microenvironment to enhance breast cancer immunotherapy using pH-responsive hybrid membrane-coated nanoparticles. *J Nanobiotechnology*. 2021;19:58.
165. Riaz N, Morris L, Havel JJ, Makarov V, Desrichard A, Chan TA. The role of neoantigens in response to immune checkpoint blockade. *Int Immunol*. 2016;28:411–9.
166. Reuben A, Spencer CN, Prieto PA, Gopalakrishnan V, Reddy SM, Miller JP, Mao X, De Macedo MP, Chen J, Song X, et al. Genomic and immune heterogeneity are associated with differential responses to therapy in melanoma. *Genom Med*. 2017;2:10.
167. McGranahan N, Furness AJ, Rosenthal R, Ramskov S, Lyngaa R, Saini SK, Jamal-Hanjani M, Wilson GA, Birkbak NJ, Hiley CT, et al. Clonal neoantigens elicit T cell immunoreactivity and sensitivity to immune checkpoint blockade. *Science*. 2016;351:1463–9.
168. Jin YB, Luo W, Zhang GY, Lin KR, Cui JH, Chen XP, Pan YM, Mao XF, Tang J, Wang YJ. TCR repertoire profiling of tumors, adjacent normal tissues, and peripheral blood predicts survival in nasopharyngeal carcinoma. *Cancer Immunol Immunother*. 2018;67:1719–30.
169. Chen R, Lee WC, Fujimoto J, Li J, Hu X, Mehran R, Rice D, Swisher SG, Sepesi B, Tran HT, et al. Evolution of genomic and T-cell repertoire heterogeneity of malignant pleural mesothelioma under dasatinib treatment. *Clin Cancer Res*. 2020;26:5477–86.
170. Bai X, Zhang Q, Wu S, Zhang X, Wang M, He F, Wei T, Yang J, Lou Y, Cai Z, Liang T. Characteristics of tumor infiltrating lymphocyte and circulating lymphocyte repertoires in pancreatic cancer by the sequencing of T cell receptors. *Sci Rep*. 2015;5:13664.
171. Zhang J, Fujimoto J, Zhang J, Wedge DC, Song X, Zhang J, Seth S, Chow CW, Cao Y, Gumbs C, et al. Intratumor heterogeneity in localized lung adenocarcinomas delineated by multiregion sequencing. *Science*. 2014;346:256–9.
172. Matsushita H, Vesely MD, Koboldt DC, Rickert CG, Uppaluri R, Magrini VJ, Arthur CD, White JM, Chen YS, Shea LK, et al. Cancer exome analysis reveals a T-cell-dependent mechanism of cancer immunoeediting. *Nature*. 2012;482:400–4.
173. Verdegaal EM, de Miranda NF, Visser M, Harryvan T, van Buuren MM, Andersen RS, Hadrup SR, van der Minne CE, Schotte R, Spits H, et al. Neoantigen landscape dynamics during human melanoma-T cell interactions. *Nature*. 2016;536:91–5.
174. McGranahan N, Rosenthal R, Hiley CT, Rowan AJ, Watkins TBK, Wilson GA, Birkbak NJ, Veeriah S, Van Loo P, Herrero J, et al. Allele-specific HLA loss and immune escape in lung cancer evolution. *Cell*. 2017;171:1259–1271 e1211.
175. Scheper W, Kelderman S, Fanchi LF, Linnemann C, Bendle G, de Rooij MAJ, Hirt C, Mezzadra R, Slagter M, Dijkstra K, et al. Low and variable tumor reactivity of the intratumoral TCR repertoire in human cancers. *Nat Med*. 2019;25:89–94.
176. Zaretsky JM, Garcia-Diaz A, Shin DS, Escuin-Ordinas H, Hugo W, Hu-Lieskovan S, Torrejon DY, Abril-Rodriguez G, Sandoval S, Barthly L, et al. Mutations associated with acquired resistance to PD-1 blockade in melanoma. *N Engl J Med*. 2016;375:819–29.
177. Gao J, Shi LZ, Zhao H, Chen J, Xiong L, He Q, Chen T, Roszik J, Bernatchez C, Woodman SE, et al. Loss of IFN-gamma pathway genes in tumor cells as a mechanism of resistance to anti-CTLA-4 therapy. *Cell*. 2016;167:397–404 e399.
178. Fish EN, Platania LC. Interferon receptor signaling in malignancy: a network of cellular pathways defining biological outcomes. *Mol Cancer Res*. 2014;12:1691–703.
179. Williams JB, Li S, Higgs EF, Cabanov A, Wang X, Huang H, Gajewski TF. Tumor heterogeneity and clonal cooperation influence the immune selection of IFN-gamma-signaling mutant cancer cells. *Nat Commun*. 2020;11:602.
180. Shin DS, Zaretsky JM, Escuin-Ordinas H, Garcia-Diaz A, Hu-Lieskovan S, Kalbasi A, Grasso CS, Hugo W, Sandoval S, Torrejon DY, et al. Primary resistance to PD-1 blockade mediated by JAK1/2 mutations. *Cancer Discov*. 2017;7:188–201.
181. Hugo W, Zaretsky JM, Sun L, Song C, Moreno BH, Hu-Lieskovan S, Berent-Maoz B, Pang J, Chmielowski B, Cherry G, et al. Genomic and transcriptomic features of response to anti-PD-1 therapy in metastatic melanoma. *Cell*. 2016;165:35–44.
182. Ayers M, Lunceford J, Nebozhyn M, Murphy E, Loboda A, Kaufman DR, Albright A, Cheng JD, Kang SP, Shankaran V, et al. IFN-gamma-related mRNA profile predicts clinical response to PD-1 blockade. *J Clin Invest*. 2017;127:2930–40.
183. Caspi E, Rosin-Arbesfeld R. A novel functional screen in human cells identifies MOCA as a negative regulator of Wnt signaling. *Mol Biol Cell*. 2008;19:4660–74.
184. Spranger S, Bao R, Gajewski TF. Melanoma-intrinsic beta-catenin signaling prevents anti-tumour immunity. *Nature*. 2015;523:231–5.
185. Yaguchi T, Goto Y, Kido K, Mochimaru H, Sakurai T, Tsukamoto N, Kudo-Saito C, Fujita T, Sumimoto H, Kawakami Y. Immune suppression and resistance mediated by constitutive activation of Wnt/beta-catenin signaling in human melanoma cells. *J Immunol*. 2012;189:2110–7.
186. Spranger S, Dai D, Horton B, Gajewski TF. Tumor-residing Batf3 dendritic cells are required for effector T cell trafficking and adoptive T cell therapy. *Cancer Cell*. 2017;31:711–723 e714.
187. Restifo NP, Smyth MJ, Snyder A. Acquired resistance to immunotherapy and future challenges. *Nat Rev Cancer*. 2016;16:121–6.
188. Sade-Feldman M, Jiao YJ, Chen JH, Rooney MS, Barzily-Rokni M, Eliane JP, Bjorgaard SL, Hammond MR, Vitzthum H, Blackmon SM, et al. Resistance to checkpoint blockade therapy through inactivation of antigen presentation. *Nat Commun*. 2017;8:1136.
189. Chapusot C, Martin L, Bouvier AM, Bonithon-Kopp C, Ecarnot-Laubriet A, Rageot D, Ponnelle T, Laurent Puig P, Faivre J, Piard F. Microsatellite instability and intratumoural heterogeneity in 100 right-sided sporadic colon carcinomas. *Br J Cancer*. 2002;87:400–4.

190. Tachon G, Frouin E, Karayan-Tapon L, Auriault ML, Godet J, Moulin V, Wang Q, Tougeron D. Heterogeneity of mismatch repair defect in colorectal cancer and its implications in clinical practice. *Eur J Cancer*. 2018;95:112–6.
191. Nava Rodrigues D, Rescigno P, Liu D, Yuan W, Carreira S, Lambros MB, Seed G, Mateo J, Riisnaes R, Mullane S, et al. Immunogenomic analyses associate immunological alterations with mismatch repair defects in prostate cancer. *J Clin Investig*. 2018;128:4441–53.
192. Kloor M, Becker C, Benner A, Woerner SM, Gebert J, Ferrone S, von Knebel DM. Immunoselective pressure and human leukocyte antigen class I antigen machinery defects in microsatellite unstable colorectal cancers. *Cancer Res*. 2005;65:6418–24.
193. Peltomaki P. Role of DNA mismatch repair defects in the pathogenesis of human cancer. *J Clin Oncol*. 2003;21:1174–9.
194. Joost P, Veurink N, Holck S, Klarskov L, Bojesen A, Harbo M, Baldetorp B, Rambech E, Nilbert M. Heterogenous mismatch-repair status in colorectal cancer. *Diagn Pathol*. 2014;9:126.
195. Llosa NJ, Lubber B, Siegel N, Awan AH, Oke T, Zhu Q, Bartlett BR, Aulakh LK, Thompson ED, Jaffee EM, et al. Immunopathologic stratification of colorectal cancer for checkpoint blockade immunotherapy. *Cancer Immunol Res*. 2019;7:1574–9.
196. Llosa NJ, Lubber B, Tam AJ, Smith KN, Siegel N, Awan AH, Fan H, Oke T, Zhang J, Domingue J, et al. Intratumoral Adaptive Immunosuppression and Type 17 Immunity in Mismatch Repair Proficient Colorectal Tumors. *Clin Cancer Res*. 2019;25:5250–9.
197. Swift SL, Duffy S, Lang SH. Impact of tumor heterogeneity and tissue sampling for genetic mutation testing: a systematic review and post hoc analysis. *J Clin Epidemiol*. 2020;126:45–55.
198. Vanderwalde A, Spetzler D, Xiao N, Gatalica Z, Marshall J. Microsatellite instability status determined by next-generation sequencing and compared with PD-L1 and tumor mutational burden in 11,348 patients. *Cancer Med*. 2018;7:746–56.
199. Salipante SJ, Scroggins SM, Hampel HL, Turner EH, Pritchard CC. Microsatellite instability detection by next generation sequencing. *Clin Chem*. 2014;60:1192–9.
200. Niu B, Ye K, Zhang Q, Lu C, Xie M, McLellan MD, Wendl MC, Ding L. MSIsensor: microsatellite instability detection using paired tumor-normal sequence data. *Bioinformatics*. 2014;30:1015–6.
201. Hempelmann JA, Lockwood CM, Konnick EQ, Schweizer MT, Antonarakis ES, Lotan TL, Montgomery B, Nelson PS, Klemfuss N, Salipante SJ, Pritchard CC. Microsatellite instability in prostate cancer by PCR or next-generation sequencing. *J Immunother Cancer*. 2018;6:29.
202. Kautto EA, Bonneville R, Miya J, Yu L, Krook MA, Reeser JW, Roychowdhury S. Performance evaluation for rapid detection of pan-cancer microsatellite instability with MANTIS. *Oncotarget*. 2017;8:7452–63.
203. Lawson DA, Kessenbrock K, Davis RT, Pervolarakis N, Werb Z. Tumour heterogeneity and metastasis at single-cell resolution. *Nat Cell Biol*. 2018;20:1349–60.
204. Hiley C, de Bruin EC, McGranahan N, Swanton C. Deciphering intratumor heterogeneity and temporal acquisition of driver events to refine precision medicine. *Genome Biol*. 2014;15:453.
205. Zhang Y, Song J, Zhao Z, Yang M, Chen M, Liu C, Ji J, Zhu D. Single-cell transcriptome analysis reveals tumor immune microenvironment heterogeneity and granulocytes enrichment in colorectal cancer liver metastases. *Cancer Lett*. 2020;470:84–94.
206. Ramakrishna S, Shah NN. Using single-cell analysis to predict CAR T cell outcomes. *Nat Med*. 2020;26:1813–4.
207. Zhou Y, Yang D, Yang Q, Lv X, Huang W, Zhou Z, Wang Y, Zhang Z, Yuan T, Ding X, et al. Single-cell RNA landscape of intratumoral heterogeneity and immunosuppressive microenvironment in advanced osteosarcoma. *Nat Commun*. 2020;11:6322.
208. Redmond D, Poran A, Elemento O. Single-cell TCRseq: paired recovery of entire T-cell alpha and beta chain transcripts in T-cell receptors from single-cell RNAseq. *Genome Med*. 2016;8:80.
209. Bradley P, Thomas PG. Using T cell receptor repertoires to understand the principles of adaptive immune recognition. *Annu Rev Immunol*. 2019;37:547–70.
210. Jiang N, Schonnesen AA, Ma KY. Ushering in integrated T cell repertoire profiling in cancer. *Trends Cancer*. 2019;5:85–94.
211. Griffiths JI, Wallet P, Pflieger LT, Stenehjem D, Liu X, Cosgrove PA, Leggett NA, McQuerry JA, Shrestha G, Rossetti M, et al. Circulating immune cell phenotype dynamics reflect the strength of tumor-immune cell interactions in patients during immunotherapy. *Proc Natl Acad Sci USA*. 2020;117:16072–82.
212. Nirschl CJ, Suarez-Farinas M, Izar B, Prakadan S, Dannenfeller R, Tirosh I, Liu Y, Zhu Q, Devi KSP, Carroll SL, et al. IFN $\gamma$ -dependent tissue-immune homeostasis is co-opted in the tumor microenvironment. *Cell*. 2017;170:127–141 e115.
213. Mitra AK, Mukherjee UK, Harding T, Jang JS, Stessman H, Li Y, Abyzov A, Jen J, Kumar S, Rajkumar V, Van Ness B. Single-cell analysis of targeted transcriptome predicts drug sensitivity of single cells within human myeloma tumors. *Leukemia*. 2016;30:1094–102.
214. Sarobe P, Corrales F. Getting insights into hepatocellular carcinoma tumour heterogeneity by multiomics dissection. *Gut*. 2019;68:1913–4.
215. Job S, Rapoud D, Dos Santos A, Gonzalez P, Desterke C, Pascal G, Elarouci N, Ayadi M, Adam R, Azoulay D, et al. Identification of Four Immune Subtypes Characterized by Distinct Composition and Functions of Tumor Microenvironment in Intrahepatic Cholangiocarcinoma. *Hepatology*. 2020;72:965–81.
216. Oxnard GR, Thress KS, Alden RS, Lawrance R, Paweletz CP, Cantarini M, Yang JC, Barrett JC, Janne PA. Association between plasma genotyping and outcomes of treatment with osimertinib (AZD9291) in advanced non-small-cell lung cancer. *J Clin Oncol*. 2016;34:3375–82.
217. Nagrath S, Sequist LV, Maheswaran S, Bell DW, Irimia D, Ulluk L, Smith MR, Kwak EL, Digumarthy S, Muzikansky A, et al. Isolation of rare circulating tumour cells in cancer patients by microchip technology. *Nature*. 2007;450:1235–9.
218. Chabon JJ, Simmons AD, Lovejoy AF, Esfahani MS, Newman AM, Haringsma HJ, Kurtz DM, Stehr H, Scherer F, Karlovich CA, et al. Circulating tumour DNA profiling reveals heterogeneity of EGFR inhibitor resistance mechanisms in lung cancer patients. *Nat Commun*. 2016;7:11815.
219. San Lucas FA, Allenson K, Bernard V, Castillo J, Kim DU, Ellis K, Ehli EA, Davies GE, Petersen JL, Li D, et al. Minimally invasive genomic and transcriptomic profiling of visceral cancers by next-generation sequencing of circulating exosomes. *Ann Oncol*. 2016;27:635–41.
220. Bettegowda C, Sausen M, Leary RJ, Kinde I, Wang Y, Agrawal N, Bartlett BR, Wang H, Lubber B, Alani RM, et al. Detection of circulating tumor DNA in early- and late-stage human malignancies. *Sci Transl Med*. 2014;6:224ra224.
221. Fojo T, Mailankody S, Lo A. Unintended consequences of expensive cancer therapeutics—the pursuit of marginal indications and a me-too mentality that stifles innovation and creativity: the John Conley Lecture. *JAMA Otolaryngol Head Neck Surg*. 2014;140:1225–36.
222. da Silva FC, Oliveira P. Tumor clone dynamics in lethal prostate cancer. *Eur Urol*. 2017;71:142–3.
223. Murtaza M, Dawson SJ, Tsui DW, Gale D, Forshew T, Piskorz AM, Parkinson C, Chin SF, Kingsbury Z, Wong AS, et al. Non-invasive analysis of acquired resistance to cancer therapy by sequencing of plasma DNA. *Nature*. 2013;497:108–12.
224. Karlovich C, Goldman JW, Sun JM, Mann E, Sequist LV, Konopa K, Wen W, Angenendt P, Horn L, Spigel D, et al. Assessment of EGFR mutation status in matched plasma and tumor tissue of NSCLC patients from a phase I study of rociletinib (CO-1686). *Clin Cancer Res*. 2016;22:2386–95.
225. Thierry AR, El Messaoudi S, Mollevi C, Raoul JL, Guimbaud R, Pezet D, Artru P, Assenat E, Borg C, Mathonnet M, et al. Clinical utility of circulating DNA analysis for rapid detection of actionable mutations to select metastatic colorectal patients for anti-EGFR treatment. *Ann Oncol*. 2017;28:2149–59.
226. Parikh AR, Leshchiner I, Elagina L, Goyal L, Levovitz C, Siravegna G, Livitz D, Rhrissorakrai K, Martin EE, Van Seventer EE, et al. Liquid versus tissue biopsy for detecting acquired resistance and tumor heterogeneity in gastrointestinal cancers. *Nat Med*. 2019;25:1415–21.
227. Zhang Y, Yao Y, Xu Y, Li L, Gong Y, Zhang K, Zhang M, Guan Y, Chang L, Xia X, et al. Pan-cancer circulating tumor DNA detection in over 10,000 Chinese patients. *Nat Commun*. 2021;12:11.
228. Nakamura Y, Taniguchi H, Ikeda M, Bando H, Kato K, Morizane C, Esaki T, Komatsu Y, Kawamoto Y, Takahashi N, et al. Clinical utility of circulating tumor DNA sequencing in advanced gastrointestinal cancer: SCRUM-Japan GI-SCREEN and GOZILA studies. *Nat Med*. 2020;26:1859–64.
229. Ritch E, Fu SYF, Herberts C, Wang G, Warner EW, Schonlau E, Taavitsainen S, Murtha AJ, Vandekerkhove G, Beja K, et al. Identification of

- Hypermutation and Defective Mismatch Repair in ctDNA from Metastatic Prostate Cancer. *Clin Cancer Res.* 2020;26:1114–25.
230. Willis J, Lefterova MI, Artyomenko A, Kasi PM, Nakamura Y, Mody K, Catenacci DVT, Fakhri M, Barbacioru C, Zhao J, et al. Validation of microsatellite instability detection using a comprehensive plasma-based genotyping panel. *Clin Cancer Res.* 2019;25:7035–45.
  231. Xi L, Pham TH, Payabyab EC, Sherry RM, Rosenberg SA, Raffeld M. Circulating tumor DNA as an early indicator of response to T-cell transfer immunotherapy in metastatic melanoma. *Clin Cancer Res.* 2016;22:5480–6.
  232. Rzhetskiy A, Kapitannikova A, Malinina P, Volovetsky A, Aboulkheyr Es H, Kulasinghe A, Thiery JP, Maslennikova A, Zvyagin AV, Ebrahimi Warkiani M. Emerging role of circulating tumor cells in immunotherapy. *Theranostics.* 2021;11:8057–75.
  233. Yue C, Jiang Y, Li P, Wang Y, Xue J, Li N, Li D, Wang R, Dang Y, Hu Z, et al. Dynamic change of PD-L1 expression on circulating tumor cells in advanced solid tumor patients undergoing PD-1 blockade therapy. *Oncoimmunology.* 2018;7:e1438111.
  234. Zhong X, Zhang H, Zhu Y, Liang Y, Yuan Z, Li J, Li J, Li X, Jia Y, He T, et al. Circulating tumor cells in cancer patients: developments and clinical applications for immunotherapy. *Mol Cancer.* 2020;19:15.
  235. Strati A, Koutsodontis G, Papaxoinis G, Angelidis I, Zavridou M, Economopoulou P, Kotsantis I, Avgeris M, Mazel M, Perisanidis C, et al. Prognostic significance of PD-L1 expression on circulating tumor cells in patients with head and neck squamous cell carcinoma. *Ann Oncol.* 2017;28:1923–33.
  236. Lin M, Liang SZ, Shi J, Niu LZ, Chen JB, Zhang MJ, Xu KC. Circulating tumor cell as a biomarker for evaluating allogeneic NK cell immunotherapy on stage IV non-small cell lung cancer. *Immunol Lett.* 2017;191:10–5.
  237. Qin Z, Chen J, Zeng J, Niu L, Xie S, Wang X, Liang Y, Wu Z, Zhang M. Effect of NK cell immunotherapy on immune function in patients with hepatic carcinoma: a preliminary clinical study. *Cancer Biol Ther.* 2017;18:323–30.
  238. Lin SY, Chang SC, Lam S, Irene Ramos R, Tran K, Ohe S, Salomon MP, Bhagat AAS, Teck Lim C, Fischer TD, et al. Prospective molecular profiling of circulating tumor cells from patients with melanoma receiving combinatorial immunotherapy. *Clin Chem.* 2020;66:169–77.
  239. Gandara DR, Paul SM, Kowanetz M, Schleifman E, Zou W, Li Y, Rittmeyer A, Fehrenbacher L, Otto G, Malboeuf C, et al. Blood-based tumor mutational burden as a predictor of clinical benefit in non-small-cell lung cancer patients treated with atezolizumab. *Nat Med.* 2018;24:1441–8.
  240. Bensch F, van der Veen EL, Lub-de Hooge MN, Jorritsma-Smit A, Boellaard R, Kok IC, Oosting SF, Schroder CP, Hiltermann TJN, van der Wekken AJ, et al. (89)Zr-atezolizumab imaging as a non-invasive approach to assess clinical response to PD-L1 blockade in cancer. *Nat Med.* 2018;24:1852–8.
  241. Chatterjee S, Lesniak WG, Gabrielson M, Lisok A, Wharram B, Sysa-Shah P, Azad BB, Pomper MG, Nimmagadda S. A humanized antibody for imaging immune checkpoint ligand PD-L1 expression in tumors. *Onco-target.* 2016;7:10215–27.
  242. Heskamp S, Hobo W, Molkenboer-Kuening JD, Olive D, Oyen WJ, Dolstra H, Boerman OC. Noninvasive imaging of tumor PD-L1 expression using radiolabeled anti-PD-L1 antibodies. *Cancer Res.* 2015;75:2928–36.
  243. Hampel H, Frankel WL, Martin E, Arnold M, Khanduja K, Kuebler P, Nakagawa H, Sotomaa K, Prior TW, Westman J, et al. Screening for the Lynch syndrome (hereditary nonpolyposis colorectal cancer). *N Engl J Med.* 2005;352:1851–60.
  244. Cortes-Ciriano I, Lee S, Park WY, Kim TM, Park PJ. A molecular portrait of microsatellite instability across multiple cancers. *Nat Commun.* 2017;8:15180.
  245. Middha S, Zhang L, Nafa K, Jayakumar G, Wong D, Kim HR, Sadowska J, Berger MF, Delair DF, Shia J, et al. Reliable pan-cancer microsatellite instability assessment by using targeted next-generation sequencing data. *JCO Precis Oncol.* 2017;2017-PO.17.00084.
  246. Zigelboim I, Goodfellow PJ, Gao F, Gibb RK, Powell MA, Rader JS, Mutch DG. Microsatellite instability and epigenetic inactivation of MLH1 and outcome of patients with endometrial carcinomas of the endometrioid type. *J Clin Oncol.* 2007;25:2042–8.
  247. National Cancer Genome Atlas Research. Comprehensive molecular characterization of gastric adenocarcinoma. *Nature.* 2014;513:202–9.
  248. Murphy MA, Wentzensen N. Frequency of mismatch repair deficiency in ovarian cancer: a systematic review This article is a US Government work and as such, is in the public domain of the United States of America. *Int J Cancer.* 2011;129:1914–22.
  249. Chiappini F, Gross-Goupil M, Saffroy R, Azoulay D, Emile JF, Veilhan LA, Delvart V, Chevalier S, Bismuth H, Debuire B, Lemoine A. Microsatellite instability mutator phenotype in hepatocellular carcinoma in non-alcoholic and non-virally infected normal livers. *Carcinogenesis.* 2004;25:541–7.
  250. Stoehr C, Burger M, Stoehr R, Bertz S, Ruummele P, Hofstaedter F, Denzinger S, Wieland WF, Hartmann A, Walter B. Mismatch repair proteins hMLH1 and hMSH2 are differentially expressed in the three main subtypes of sporadic renal cell carcinoma. *Pathobiology.* 2012;79:162–8.
  251. Schneider B, Glass A, Jagdmann S, Huhns M, Claus J, Zettl H, Dräger DL, Maruschke M, Hakenberg OW, Erbersdobler A, Zimpfer A. Loss of mismatch-repair protein expression and microsatellite instability in upper tract urothelial carcinoma and clinicopathologic implications. *Clin Genitourin Cancer.* 2020;18:e563–72.
  252. Ruummele P, Dietmaier W, Terracciano L, Tornillo L, Bataille F, Kaiser A, Wuensch PH, Heinmoeller E, Homayounfar K, Luettgies J, et al. Histopathologic features and microsatellite instability of cancers of the papilla of Vater and their precursor lesions. *Am J Surg Pathol.* 2009;33:691–704.
  253. Karpinska-Kaczmarczyk K, Lewandowska M, Lawniczak M, Bialek A, Urasinska E. Expression of mismatch repair proteins in early and advanced gastric cancer in Poland. *Med Sci Monit.* 2016;22:2886–92.
  254. Lee-Kong SA, Markowitz AJ, Glogowski E, Papadopoulos C, Stadler Z, Weiser MR, Temple LK, Guillem JG. Prospective immunohistochemical analysis of primary colorectal cancers for loss of mismatch repair protein expression. *Clin Colorectal Cancer.* 2010;9:255–9.
  255. Tessier-Cloutier B, Schaeffer DF, Bacani J, Marginean CE, Kalloger S, Kobel M, Lee CH. Loss of switch/sucrose non-fermenting complex protein expression in undifferentiated gastrointestinal and pancreatic carcinomas. *Histopathology.* 2020;77:46–54.
  256. Caccese M, Ius T, Simonelli M, Fassan M, Cesselli D, Dipasquale A, Cavallin F, Padovan M, Salvalaggio A, Gardiman MP, et al. Mismatch-repair protein expression in high-grade gliomas: a large retrospective multicenter study. *Int J Mol Sci.* 2020;21:6716.
  257. Indraccolo S, Lombardi G, Fassan M, Pasqualini L, Giunco S, Marcato R, Gasparini A, Candiotti C, Nalio S, Fiduccia P, et al. Genetic, epigenetic, and immunologic profiling of MMR-deficient relapsed glioblastoma. *Clin Cancer Res.* 2019;25:1828–37.
  258. Sharma M, Yang Z, Miyamoto H. Loss of DNA mismatch repair proteins in prostate cancer. *Medicine (Baltimore).* 2020;99:e20124.
  259. Huang HN, Kuo CW, Lin MC, Mao TL, Kuo KT. Frequent CTNBN1 or PIK3CA mutations occurred in endometrial endometrioid adenocarcinoma with high levels of microsatellite instability and loss of MSH2/MSH6 expression. *Appl Immunohistochem Mol Morphol.* 2020;28:284–9.
  260. de Jong RA, Boerma A, Boezen HM, Mourits MJ, Hollema H, Nijman HW. Loss of HLA class I and mismatch repair protein expression in sporadic endometrioid endometrial carcinomas. *Int J Cancer.* 2012;131:1828–36.
  261. Poulsen TS, de Oliveira D, Espersen MLM, Klarskov LL, Skovrider-Ruminski W, Hogdall E. Frequency and coexistence of KRAS, NRAS, BRAF and PIK3CA mutations and occurrence of MMR deficiency in Danish colorectal cancer patients. *APMIS.* 2021;129:61–9.
  262. Sarode VR, Robinson L. Screening for lynch syndrome by immunohistochemistry of mismatch repair proteins: significance of indeterminate result and correlation with mutational studies. *Arch Pathol Lab Med.* 2019;143:1225–33.
  263. House MG, Herman JG, Guo MZ, Hooker CM, Schulick RD, Lillemo KD, Cameron JL, Hruban RH, Maitra A, Yeo CJ. Aberrant hypermethylation of tumor suppressor genes in pancreatic endocrine neoplasms. *Ann Surg.* 2003;238:423–31 (**discussion 431–422**).
  264. Mei M, Deng D, Liu TH, Sang XT, Lu X, Xiang HD, Zhou J, Wu H, Yang Y, Chen J, et al. Clinical implications of microsatellite instability and MLH1 gene inactivation in sporadic insulinomas. *J Clin Endocrinol Metab.* 2009;94:3448–57.
  265. Lavin Y, Kobayashi S, Leader A, Amir ED, Elefant N, Bigenwald C, Remark R, Sweeney R, Becker CD, Levine JH, et al. Innate immune landscape

- in early lung adenocarcinoma by paired single-cell analyses. *Cell*. 2017;169:750–765 e717.
266. Yan T, Cui H, Zhou Y, Yang B, Kong P, Zhang Y, Liu Y, Wang B, Cheng Y, Li J, et al. Multi-region sequencing unveils novel actionable targets and spatial heterogeneity in esophageal squamous cell carcinoma. *Nat Commun*. 2019;10:1670.
  267. Sherwood AM, Emerson RO, Scherer D, Habermann N, Buck K, Staffa J, Desmarais C, Halama N, Jaeger D, Schirmacher P, et al. Tumor-infiltrating lymphocytes in colorectal tumors display a diversity of T cell receptor sequences that differ from the T cells in adjacent mucosal tissue. *Cancer Immunol Immunother*. 2013;62:1453–61.
  268. Zhang AW, McPherson A, Milne K, Kroeger DR, Hamilton PT, Miranda A, Funnell T, Little N, de Souza CPE, Laan S, et al. Interfaces of malignant and immunologic clonal dynamics in ovarian cancer. *Cell*. 2018;173:1755–1769 e1722.
  269. Yuzhakova DV, Volchkova LN, Pogorelyy MV, Serebrovskaya EO, Shagina IA, Bryushkova EA, Nakonechnaya TO, Izosimova AV, Zavyalova DS, Karabut MM, et al. Measuring intratumoral heterogeneity of immune repertoires. *Front Oncol*. 2020;10:512.
  270. Tirosh I, Izar B, Prakasam LN, Wadsworth MH 2nd, Treacy D, Trombetta JJ, Rotem A, Rodman C, Lian C, Murphy G, et al. Dissecting the multi-cellular ecosystem of metastatic melanoma by single-cell RNA-seq. *Science*. 2016;352:189–96.
  271. Gerlinger M, Quezada SA, Peggs KS, Furness AJ, Fisher R, Marafioti T, Shende VH, McGranahan N, Rowan AJ, Hazell S, et al. Ultra-deep T cell receptor sequencing reveals the complexity and intratumour heterogeneity of T cell clones in renal cell carcinomas. *J Pathol*. 2013;231:424–32.
  272. Jiménez-Sánchez A, Memon D, Pourpe S, Veeraraghavan H, Li Y, Vargas HA, Gill MB, Park KJ, Zivanovic O, Konner J, et al. Heterogeneous tumor-immune microenvironments among differentially growing metastases in an ovarian cancer patient. *Cell*. 2017;170:927–938.e920.
  273. Emerson RO, Sherwood AM, Rieder MJ, Guenthoer J, Williamson DW, Carlson CS, Drescher CW, Tewari M, Bielas JH, Robins HS. High-throughput sequencing of T-cell receptors reveals a homogeneous repertoire of tumour-infiltrating lymphocytes in ovarian cancer. *J Pathol*. 2013;231:433–40.
  274. Wang T, Wang C, Wu J, He C, Zhang W, Liu J, Zhang R, Lv Y, Li Y, Zeng X, et al. The different T-cell receptor repertoires in breast cancer tumors, draining lymph nodes, and adjacent tissues. *Cancer Immunol Res*. 2017;5:148–56.
  275. Pasetto A, Gros A, Robbins PF, Deniger DC, Prickett TD, Matus-Nicodemus R, Douek DC, Howie B, Robins H, Parkhurst MR, et al. Tumor- and neoantigen-reactive T-cell receptors can be identified based on their frequency in fresh tumor. *Cancer Immunol Res*. 2016;4:734–43.
  276. Sheng J, Wang H, Liu X, Deng Y, Yu Y, Xu P, Shou J, Pan H, Li H, Zhou X, et al. Deep sequencing of T-cell receptors for monitoring peripheral CD8(+) T cells in chinese advanced non-small-cell lung cancer patients treated with the anti-PD-L1 antibody. *Front Mol Biosci*. 2021;8:679130.
  277. Wang J, Bie Z, Zhang Y, Li L, Zhu Y, Zhang Y, Nie X, Zhang P, Cheng G, Di X, et al. Prognostic value of the baseline circulating T cell receptor beta chain diversity in advanced lung cancer. *Oncoimmunology*. 2021;10:1899609.
  278. Aoki H, Ueha S, Shichino S, Ogiwara H, Hashimoto SI, Kakimi K, Ito S, Matsushima K. TCR repertoire analysis reveals mobilization of novel CD8(+) T cell clones into the cancer-immunity cycle following anti-CD4 antibody administration. *Front Immunol*. 2018;9:3185.
  279. Angelova M, Mlecnik B, Vasaturo A, Bindea G, Fredriksen T, Lafontaine L, Buttard B, Morgand E, Bruni D, Jouret-Mourin A, et al. Evolution of metastases in space and time under immune selection. *Cell*. 2018;175:751–765 e716.
  280. Le DT, Kim TW, Van Cutsem E, Geva R, Jager D, Hara H, Burge M, O'Neil B, Kavan P, Yoshino T, et al. Phase II open-label study of pembrolizumab in treatment-refractory, microsatellite instability-high/mismatch repair-deficient metastatic colorectal cancer: KEYNOTE-164. *J Clin Oncol*. 2020;38:11–9.
  281. Marabelle A, Le DT, Ascierto PA, Di Giacomo AM, De Jesus-Acosta A, Delord JP, Geva R, Gottfried M, Penel N, Hansen AR, et al. Efficacy of pembrolizumab in patients with noncolorectal high microsatellite instability/mismatch repair-deficient cancer: results from the phase II KEYNOTE-158 study. *J Clin Oncol*. 2020;38:1–10.
  282. Abida W, Cheng ML, Armenia J, Middha S, Autio KA, Vargas HA, Rathkopf D, Morris MJ, Danila DC, Slovin SF, et al. Analysis of the prevalence of microsatellite instability in prostate cancer and response to immune checkpoint blockade. *JAMA Oncol*. 2019;5:471–8.
  283. Andre T, Shiu KK, Kim TW, Jensen BV, Jensen LH, Punt C, Smith D, Garcia-Carbonero R, Benavides M, Gibbs P, et al. Pembrolizumab in microsatellite-instability-high advanced colorectal cancer. *N Engl J Med*. 2020;383:2207–18.
  284. Wang Z, Duan J, Cai S, Han M, Dong H, Zhao J, Zhu B, Wang S, Zhuo M, Sun J, et al. Assessment of blood tumor mutational burden as a potential biomarker for immunotherapy in patients with non-small cell lung cancer with use of a next-generation sequencing cancer gene panel. *JAMA Oncol*. 2019;5:696–702.
  285. Cristescu R, Mogg R, Ayers M, Albright A, Murphy E, Yearley J, Sher X, Liu XQ, Lu H, Nebozhyn M, et al. Pan-tumor genomic biomarkers for PD-1 checkpoint blockade-based immunotherapy. *Science*. 2018;362:eaar3593.

## Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Ready to submit your research? Choose BMC and benefit from:

- fast, convenient online submission
- thorough peer review by experienced researchers in your field
- rapid publication on acceptance
- support for research data, including large and complex data types
- gold Open Access which fosters wider collaboration and increased citations
- maximum visibility for your research: over 100M website views per year

At BMC, research is always in progress.

Learn more [biomedcentral.com/submissions](https://biomedcentral.com/submissions)

